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Chapter 1 – Introduction 
 Endocrine disruptors, xenobiotics, environmental obesogens, persistent organic 
pollutants and environmental toxicants are all terms used to describe chemicals in the 
environment that affect human and/or animal health.  Some are naturally occurring 
substances (e.g. mercury, lead, and radon), but the majority are synthetic compounds 
(e.g. Bisphenol A, phthalates, pesticides and dioxins) introduced into the environment 
by man, only to later discover their deleterious effects on humans and wildlife. 
Many naturally occurring (non-synthetic) environmental toxicants fall under the 
classification of heavy metals (e.g. lead, mercury, arsenic and cadmium).  They are 
considered to be persistent environmental contaminants, found in their most basic 
elemental forms and can’t be further broken down or destroyed.  Multiple health effects 
are associated with heavy metal exposure.  Arsenic has been shown to cause weight 
loss, central nervous system deficits, respiratory and reproductive system 
complications, and diabetes and lung cancer [1-4].  Mercury exposure has been shown 
to affect renal, respiratory, cardiovascular, gastrointestinal and central nervous systems 
[5].  Lead (Pb) exposure has been associated with loss of cognitive function, renal and 
central nervous system impairments, hypertension, anemia and thyroid hormone 
imbalances [6-16].  Although the sources of some of these heavy metals, such as Pb, 
have been eliminated (e.g. from paints and gasoline), other Pb-containing sources like 
industrially contaminated soils and turn-of-the-century housing, prevalent in urban areas 
like Detroit, remain a significant exposure risk throughout residents’ lifetimes [17-20].   
Synthetic, or man-made toxicants, are numerous and pose risks for diseases 
associated with exposure [21].  Synthetic toxicants include, but are not limited to, 
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polybrominated diphenylethers (PBDEs), polychlorinated biphenyls (PCBs), phthalates, 
organochlorinated pesticides (e.g. DDT), Bisphenol A (BPA), perfluorinated compounds 
(PFCs) and dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) or dioxin-like 
compounds.  PBDEs are flame retardant chemicals known to impair liver and thyroid 
function as well as cause cancer [22-24].  Phthalates increase flexibility in plastics 
products, are used to add fragrances to everyday items, and are known to cause 
testicular dysgenesis, asthma and have recently been linked to thyroid dysfunction, 
obesity and diabetes [25-29].  Dioxins are a by-product of plastics manufacturing, they 
are known to affect whole-body energy metabolism and interfere with thyroid function as 
well as cause peripheral insulin resistance, cancer and diabetes [30-42].  
An important and unresolved question in the environmental health field is 
whether exposure to common environmental toxicants, such as dioxin and heavy metal 
like Pb, increase the risk of developing diabetes, especially in those populations 
subjected to concomitant risk factors such as obesity.  Currently, 11.3% of adults in the 
US are diabetic and NIH reports indicate steady increases in diabetes diagnoses since 
1990 [43].  Obesity, which is found in greater than one third of the US population (72 
million people), is strongly associated with diabetes and the metabolic syndrome [44]. 
High obesity rates may be attributed to the social/behavioral stressors of physical 
inactivity and over-nutrition, yet this issue can be viewed from the perspective of 
potential pathological interactions between different classes of environmental stressors - 
chemical (exposure to environmental toxicants) and social (lifestyle behaviors leading to 
obesity).   
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With a vast array of literature describing its deleterious effects, dioxin is one of 
the most studied environmental toxicants.  Links have been established between dioxin 
exposure and peripheral insulin resistance, however, there was no evidence of elevated 
blood glucose levels or fasting hyperglycemia [35, 39, 42, 45-47].  The development of 
insulin resistance is correlated with an increased risk of developing diabetes and is a 
clinical symptom of type 2 diabetes mellitus as are elevated blood glucose levels and 
fasting hyperglycemia.  Data suggests that exposure to dioxin may result in the 
suppression of hepatic glucose production causing hypoglycemia due to increased 
insulin levels and/or transcriptional suppression of phosphoenolpyruvate carboxykinase 
(PEPCK) gene expression [30, 34, 38, 39, 47].  While dioxin exposure is not prevalent 
in human populations, the mechanism of action is well established having been found to 
be primarily mediated by activation of the aryl hydrocarbon receptor (AhR) [48-54].  
In contrast to dioxin, the mechanism of action for the physiological effects of Pb 
exposure is less well established, however, human exposures are much more 
widespread.  Pb is of particular interest because there is some evidence that exposure 
affects metabolism and data presented herein suggests that chronic Pb exposure 
contributes to development of diabetes in obese rats. The Pb-obesity interaction is a 
relevant issue in large sections of the US population where environmental stressors of 
over-nutrition (taking in more calories than the body needs) and an inactive or sedentary 
lifestyle are common and co-exist with exposure to persistent environmental toxicants, 
such as Pb.  This is certainly the case in the City of Detroit where obesity and diabetes 
rates are above the national average, and Pb exposure is relatively common (described 
in more detail in the Background). 
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 The overall goal of our lab is to examine the possibility that exposure to 
environmental toxicants increases the susceptibility and/or severity of diabetes in 
metabolically and nutritionally stressed populations.  The goal of this PhD project is two-
fold: 1) characterize the effect and determine the molecular mechanism of dioxin 
exposure on hepatic gluconeogenic gene expression and 2) characterize the effect of 
Pb exposure on diabetes risk in metabolically stressed rodents and identify the 
molecular and cellular mechanisms by which it affects metabolic balance.   These are 
initial steps in a broader research objective to determine if there is a cooperative 
interaction between environmental toxicant exposure and additional stressors from the 
physical and social environment that promote metabolic instability and disease.   
 Results from this work could have a significant impact on how we view the 
interaction of environmental toxicants with behavioral and lifestyle stressors in humans, 
and may compel others to carry out epidemiologic studies to assess the risks of toxicant 
exposure in metabolically and nutritionally stressed populations. The in vivo models 
developed here may prove useful in developing therapies to reduce the deleterious 
effects of Pb exposure in at-risk humans. Finally, the in vitro systems that I establish will 
be of general utility for research on the interaction of other environmental toxicants and 
metabolically stressed individuals. 
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Chapter 2 – Background 
2.1 – Diabetes 
Diabetes is a leading cause of death and disability in the United States, affecting 
over 10% of the adult population.  More alarming than the diagnosed diabetes 
percentage is the estimation that 26% of the adult population has impaired fasting blood 
glucose, defined as fasting blood glucose levels between normal and diabetes 
(>100mg/dL - <125mg/dL) [55].  These estimations point to greater than one quarter of 
the population having, or being likely to develop, diabetes [56].  The incidence of 
diabetes has been increasing steadily, with the number of diagnosed cases increasing 
approximately 2.5-fold between 1990 and 2005 [56].  Although the causes of the high 
incidence and increasing rate of diabetes are not well understood, multiple 
environmental factors have been suggested to contribute to disease susceptibility.  In 
particular, environment/lifestyle factors such as over nutrition (caloric overload) and 
physical inactivity (sedentary lifestyle) are believed to increase susceptibility to diabetes.  
These factors are hypothesized to contribute to the parallel rise in obesity (estimated to 
be 32% in 2007), which contributes to diabetes susceptibility in complex and poorly 
understood ways. 
Research studies have enhanced the appreciation of the integral involvement of 
molecular mechanisms such as oxidative stress and inflammation in the development of 
insulin resistance and diabetes [57-59].  One of the earliest detectable precursors of 
type 2 diabetes, and a known contributor to the development of hyperglycemia, is 
insulin resistance [60].  Hyperglycemia has been linked to the presence of oxidative 
stress as well as increased production of reactive oxygen species (ROS), all of which 
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can exacerbate insulin resistance [60-62].  Studies have shown that levels of oxidative 
stress biomarkers are altered in diabetics and people who are insulin resistant [63-65].   
The mechanisms by which hyperglycemia induces oxidative stress are not fully 
understood.  One possible scenario is that changes in cellular metabolism caused by 
hyperglycemia alter mitochondrial function leading to overproduction of superoxide 
radicals (O2˙-) by the mitochondrial electron transport chain [58, 59, 62, 66-74].  
Likewise, the mechanisms by which elevated ROS increase insulin resistance and other 
diabetes-related parameters are poorly understood.  Possible links between ROS and 
insulin resistance include increased levels of advanced glycation end-products (AGE), 
increased polyol and/or hexosamine pathway fluxes, and activation of specific protein 
kinase C (PKC) isoforms.  Hyperglycemia has been shown to induce each of the 
aforementioned processes; even a postprandial acute rise in glucose levels can induce 
these processes [60, 61].   
Increased ROS production can also stimulate activation of inflammatory signals 
(tumor necrosis factor-α [TNF-α]) and stress-response genes (JNK/SAPK, p38 MAPK, 
NF-κB), and inflict oxidative damage that interferes with the insulin signaling pathway 
[62, 70, 72, 75-92].  ROS presence is increased in diabetes [57, 60, 93] and obesity [58, 
94], where the presence of ROS has been coupled with a chronic low-level 
inflammatory condition [62].  It has been demonstrated that diabetics exhibit an 
abnormal response to hyperglycemia with reduced antioxidant enzyme expression [95, 
96].  The reduction in antioxidant enzyme expression does not allow the cell to detoxify 
the ROS adequately, resulting in elevated levels of oxidative stress, cellular damage 
and inflammatory mediators, all of which can interfere with insulin signaling. 
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There are regional variations in diabetes rates suggesting that exposure to 
specific localized environmental conditions may also influence disease susceptibility.  
Although there are many reasons for regional variations in disease rates, one possibility 
is that specific environmental contaminants present in some areas increase 
susceptibility to certain diseases.  Environmental toxicants such as dioxin and heavy 
metals such as lead (Pb) have been shown to cause oxidative stress both in vivo and in 
vitro [32, 97].  Exposure to Pb and dioxin has been shown to influence metabolism and 
may, therefore, increase susceptibility to Type 2 diabetes in exposed individuals [39, 57, 
98-100].  Given the relationship between oxidative stress and diabetes, exposure to 
environmental toxicants capable of causing oxidative stress is likely to increase 
diabetes susceptibility.    
 
2.2 – Glucose Production and Utilization 
A significant portion of my thesis work is focused on the effects of environmental 
toxicants on glucose homeostasis in general and hepatic glucose metabolism in 
particular.  The following is a brief overview of the relevant physiologies.  
The balance between glucose production and utilization is regulated by a 
network of hormones, neural pathways, and metabolic signals.  Insulin plays a pivotal 
role in this process.  In the fasting state, insulin secretion is low, which leads to 
increased gluconeogenesis in the liver and kidneys and increased glucose generation 
by the breakdown of liver glycogen. In the fed state, insulin released from pancreatic β-
cells reverses this process by inhibiting glycogenolysis and gluconeogenesis, enhancing 
peripheral glucose uptake and utilization, and lipogenesis and protein synthesis.  The 
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net result is that excess glucose is converted to glycogen, triglycerides (TGs), and 
protein.  When more glucose is present in liver cells than can be metabolized or stored 
as glycogen, insulin causes the excess glucose to be converted into free fatty acids 
(FFAs).  These FFAs are packaged as TGs in VLDL, transported in the blood in this 
form, and deposited as fat in adipose tissue.  
 
2.3 – Gluconeogenesis and Regulation of Gluconeogenic Gene Expression 
Phosphoenolpyruvate carboxykinase (PEPCK) is the rate-limiting enzyme in the 
gluconeogenesis pathway, its regulation is controlled primarily at the level of gene 
transcription and it is central to the management of hepatic glucose production during 
fasting [101].  The crucial role of PEPCK in controlling the temporal fluctuations in 
hepatic glucose output, and the fact that its regulation occurs mainly at the level of 
transcription, has made the PEPCK promoter one of the most highly studied 
transcriptional regulatory regions in the eukaryotic genome.  The signaling pathways 
and many of the transcription factors and cofactors that mediate the hormonal 
regulation of PEPCK gene transcription have been identified and a large number of 
molecular tools are available for studying the transcriptional regulation of this gene.  The 
combination of its central role in the regulation of hepatic glucose metabolism, and our 
detailed understanding of how its transcriptional activity is regulated, make the PEPCK 
gene an ideal candidate for deciphering the molecular effects of environmental toxicants 
on the regulation of hepatic glucose production [101].  The regulatory mechanisms that 
control the transcriptional activity of the PEPCK gene in response to metabolic signals 
are complex and full description is beyond the scope of this background section.  Only 
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those specific regulatory mechanisms that control PEPCK gene transcription that are 
relevant to this project will be discussed.   
Between meals and during a fast, the liver contributes to blood glucose level 
maintenance by increasing gluconeogenesis and glycogenolysis.  The increase in 
gluconeogenesis under these conditions is mediated by glucagon, and to some degree 
glucocorticoids.  Glucagon stimulates PEPCK gene transcription by activation of the 
PKA signaling pathway and the stimulation of the transcription factor CREB (Fig. 1, 
Fasted).  CREB stimulates PEPCK gene expression via direct action on the PEPCK 
promoter as well as by stimulating expression of PPARγ co-activator 1-α (PGC1-α).  
PGC1-α is a well-characterized transcriptional co-factor for many metabolic genes [102] 
and functions as a transcriptional co-activator for HNF4-α, a key component of the 
PEPCK transcriptional complex [102, 103].  
After a meal, glucagon levels fall and insulin levels rise, setting off a chain of 
events that result in the down-regulation of PEPCK gene expression.   Without glucagon 
present, PKA is no longer stimulated and CREB activation declines.  As CREB activity 
falls, its stimulatory effect on both PEPCK and PGC1-α is reduced.  The loss of PGC1- 
α also reduces the transcriptional activity of HNF4-α, which together contributes to a 
reduction of PEPCK transcription.  Finally, insulin activates Akt, which directly 
phosphorylates forkhead box protein O1 (FoxO1), causing its nuclear exclusion (Fig. 1, 
Fed).  The loss of FoxO1 from the nucleus further contributes to the down-regulation of 
PEPCK expression by insulin.  The overall effect of these events on PEPCK gene 
transcription leads to a decrease in hepatic glucose production.  External signals, such 
as exposure to environmental toxicants that alter the activity of any of these signaling 
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molecules or transcription factors and co-factors could have a significant effect on 
hepatic glucose production and whole body glucose homeostasis. 
 
 
 
  
Fig. 2.1 – Regulation of PEPCK gene transcription.   
In the fasted state, PEPCK is stimulated by glucagon (top), and in the 
fed state is suppressed by insulin (bottom). 
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2.3 – Toxicants Known to Affect Diabetes Susceptibility 
 The incidence of diabetes in the US population is at an all-time high and is 
continuing to rise each year.  Although little progress has been made in slowing the 
growth of the disease, great strides have been made in our understanding of the 
molecular causes of diabetes and its associated metabolic abnormalities such as insulin 
resistance, obesity, hyperlipidemia and hypertension.  One result of this increased 
knowledge is an appreciation of the important role that oxidative stress plays in the 
development of the disease [57-59]. Many toxicants, and in particular metals, are known 
to induce oxidative stress in exposed cells and organisms (reviewed in more detail 
below).  Given the clear role of oxidative stress in diabetes it seems reasonable to ask if 
exposure to environmental toxicants, especially those with pro-oxidant activity, could 
increase susceptibility to diabetes and related metabolic disorders.   
This is an especially relevant question if one considers the pervasiveness of 
environmental toxicants in industrialized countries.  Taken together, these issues can be 
rephrased into a simple, experimentally approachable question, does exposure to 
specific environmental toxicants increase diabetes susceptibility or severity.  There is 
some evidence that general exposures to environmental toxicants can affect diabetes 
susceptibility.   For example, a recent report demonstrated that individuals living in the 
vicinity of known toxic waste sites were more likely to be hospitalized for diabetes then 
individuals living further from such sites [104].  While a specific toxicant cannot be 
implicated in this study, it supports the general idea that toxicant-induced environmental 
stress increases the risk of developing diabetes. 
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Obviously, all toxicants do not affect physiology by the same molecular 
mechanism.  Different toxicants affect expression of the distinct sets of genes, and alter 
the activities of different enzymes.  Even with regard to the effect of metals on diabetes, 
there are wide differences in which aspects of diseases are affected by exposure to 
different toxicants.  Cadmium (Cd) has been shown to increase G6Pase, fructose-1,6-
bisphosphatase, PEPCK and total hepatic glucose output both in vivo and in vitro [105-
108].  Arsenic (Ar) has been shown to induce changes in expression of genes related to 
Type 2 diabetes and many diabetics have been shown to have high body burdens of Ar 
[109-112].  Mercury (Hg), Pb, Cd and Ar have all been shown to induce oxidative stress 
and the formation of ROS [106, 113-124], which have been associated with increased 
insulin resistance [60-62].  
Persistent organic pollutants (POPs) and organochlorinated pesticides like PCBs 
and DDT exposure were found to be significantly associated with diabetes diagnoses 
when NHANES data were evaluated by Everett et.al. [125].  A 2009 study of Great 
Lakes sport fishermen found that, of those subjects that were diabetic, they also 
possessed much higher body burdens of both PCBs and p,p’-diphenyldichloroethene 
(DDE, a congener of DDT) [126].  Finally, Vasiliu et.al. found a statistically significant 
relation between female diabetics and blood levels of PCBs, but not with male diabetics 
[127]. 
More recently, studies have found an association between increased waist 
circumference, insulin resistance and blood levels of phthalates, indicating a link not 
only between phthalate exposure and diabetes, but also between phthalates and 
obesity [29, 128, 129]. Bisphenol A (BPA) exposure has been linked to an increased 
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risk of obesity [130] as well as adiponectin inhibition (leading to a loss of insulin 
sensitivity), hyperinsulinemia, insulin resistance and glucose intolerance in rodents 
[131-133] 
Because many of the known environmental toxicants are bioaccumulative, and 
exposure can occur repeatedly throughout life, the effects of exposure may not be fully 
evident until later in life.  While it is known that toxicants are capable of causing effects 
alone, scientists are just beginning to explore multiple toxicant exposures, and evidence 
thus far demonstrates greater detrimental effects in co-exposure scenarios.   Overall, it 
is clear from the findings presented above (which are representative of a larger body of 
data), that in general exposure of the population of environmental toxicants is likely to 
have a significant impact on metabolic disease susceptibility. 
   
2.4 – Dioxin 
My initial foray into exploring mechanisms by which environmental toxicants 
affect metabolic regulation examined the effects of dioxin on hepatic gluconeogenesis 
(described in Chapter 4, below).  The following is a brief summary of background 
information on dioxin designed to provide the necessary information for this part of the 
study. 
Dioxins are a group of widely disseminated, persistent environmental 
contaminants that can have effects on whole-body energy metabolism [30-34].  In both 
in vitro and in vivo models, dioxin exposure has been shown to increase superoxide 
dismutase (SOD) activity and oxidative stress enzymes, and to cause peripheral insulin 
resistance [32, 35, 36, 134].  Peripheral insulin resistance is correlated with an 
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increased risk of developing diabetes and is a clinical symptom of type 2 diabetes 
mellitus [135-137]. 
 
2.4.1 – Dioxin and Diabetes 
There is clear evidence that dioxin exposure increases the risk of developing 
insulin resistance, a condition that often precedes and always accompanies Type 2 
diabetes.  In in vivo models subjected to a high fat sucrose diet, obesity and insulin 
resistance were observed although the animals did not develop full-scale diabetes [36].  
Similar findings have been reported in human subjects.  A recent analysis of diabetes 
parameters in human epidemiological studies conducted on Vietnam veterans from 
Operation Ranch Hand, as well as persons subjected to accident or work-related dioxin 
exposures, patients showed a strong positive correlation between dioxin exposure, 
hyperinsulinemia and insulin resistance [31, 33, 35-37, 138, 139].  Interestingly, these 
same subjects did not demonstrate abnormal fasting blood glucose levels, fasting 
hyperglycemia and were not diabetic [31, 33, 35, 37, 138], suggesting that one of the 
effects of dioxin exposure may be to suppress hepatic glucose output. 
This would be consistent with observations from dioxin treated rats where 
hypoglycemia was observed that was caused, at least in part, by reduced hepatic 
glucose production [30, 47, 140].  Together, these findings suggest that dioxin inhibits 
hepatic glucose production by suppressing expression of gluconeogenic genes.  Such 
results have indeed been reported for the hepatic gluconeogenic genes PEPCK and 
glucose-6-phosphatase (G6Pase) [30, 34, 38, 39, 47, 140], although not all studies 
were in agreement with these observations [99].   Although its effects on metabolism 
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are obviously not well understood, dioxin is a clear example of an environmental toxin 
that modulates metabolism in a way that could interact negatively with other deleterious 
environmental conditions (e.g. over-nutrition and inactivity) to alter susceptibility to 
diabetes.   
 
2.4.2 – Aryl hydrocarbon Receptor Primarily Mediates Dioxin Effects  
 The effects of dioxins are primarily mediated by activation of the aryl hydrocarbon 
receptor, AhR [48-54].  However, my data (described in this thesis) and a previously 
published study have suggested an alternative mechanism whereby dioxin may be 
suppressing PEPCK and G6Pase gene expression, via activation of AMPK [34].  AMPK 
is a cellular energy-sensing protein that is activated when AMP levels within the cell 
become high [141].  The ability of AMPK to suppress the key gluconeogenic genes 
PEPCK and G6Pase demonstrates its importance as a regulator of hepatic glucose 
production and as a potential target of dioxin.  While the effects of dioxin on AMPK and 
energy metabolism are not clearly understood, AMPK regulates a variety of metabolic 
pathways and its activation by an environmental toxicant would constitute a mechanistic 
link between toxicant exposure and the regulation of metabolism. 
 
2.4.3 – Hypotheses and Aims of Dioxin Project 
It is clear that dioxins are a persistent environmental contaminant with the ability 
to influence glucose metabolism and possibly lead to alterations in diabetes 
susceptibility.  
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Because of this possibility, the following hypotheses were formed: (1) Exposure 
to dioxin alters hepatic gluconeogenic gene expression. (2) Dioxin-mediated AMPK 
activation contributes to the suppression of hepatic glucose production. These 
hypotheses were tested by two specific aims: (1) Characterization of the effect of dioxin 
on hepatic gluconeogenic gene expression. (2) Determination of the molecular 
mechanism(s) by which dioxins alter PEPCK gene expression. 
 
2.5 – Lead (Pb) 
The majority of this thesis is focused on the effects of Pb exposure on diabetes 
susceptibility in obese rodents (described in Chapters 5 and 6, below).  The following is 
a brief summary of background information on Pb designed to provide the necessary 
information for this part of the study. 
Pb is a persistent environmental contaminant that is found in high levels in many 
urban and industrial areas.  Although it has been studied extensively in relation to 
cognitive and behavioral effects, little attention has been given to its potential 
involvement in metabolic diseases such as diabetes.  The Pb-obesity interaction is a 
relevant topic in large sections of the US population where environmental stressors of 
over-nutrition (taking in more calories than the body needs) and an inactive or sedentary 
lifestyle, are common and co-exist with exposure to persistent environmental toxicants, 
such as Pb. This is the case in the city of Detroit where obesity and diabetes rates are 
above the national average, and Pb exposure is relatively common (as described 
below). 
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In spite of the fact that there are no epidemiological studies directly addressing 
the possibility that Pb exposure enhances diabetes severity, there are several lines of 
evidence, in addition to my findings in obese rats, suggesting that Pb exposure 
promotes metabolic instability and diabetes.  
 
2.5.1 – Pb Exposure in the Human Population 
Although Pb exposure and blood lead levels have generally declined over the 
past decade, Pb body burdens continue to rank as major health concerns, particularly in 
urban areas and especially in young children and adolescents [142].  Sources of Pb 
exposure include pre-1950s housing (e.g. over 38,000,000 homes), lead based paint 
available until the 1970s, and contaminated soil in areas surrounding existing superfund 
hazardous waste sites, neighborhood industrial activities, and pre-existing conditions, 
such as the former presence of Pb smelters in urban neighborhoods.  The highly 
industrialized areas with existing Pb contamination largely contain urban under-
privileged/under-served populations.  In the city of Detroit for example, 6.4% of children 
under the age of 6 were classified as having elevated blood lead levels (> 10 μg/dL) by 
the Michigan Department of Human Health in 2003 [143].   
Pb is a ubiquitous contaminant with long half-life in vivo (10 to 38 months 
depending on exposure, blood and bone levels), which could increase the long-term 
effects of a limited exposure to Pb.  It is found in nature as a divalent cation [144], and 
has no known biological function in humans.  Pb has been shown to interfere with Fe, 
Zn2+, Ca2+ & Ca2+ -regulated events [145, 146], and to bind phospholipids thereby 
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altering membrane permeability [147].  Any of these actions could have multiple and 
widespread secondary effects on many aspects of cellular and organismal physiology.   
 
2.5.2 – Pb Causes Oxidative Stress, a Risk Factor for Diabetes 
Like many toxicants, Pb induces oxidative stress in vitro and in vivo, a known risk 
factor for the development of insulin resistance and diabetes [57, 93].  The ability of Pb 
to catalyze oxidative reactions and generate reactive oxygen species (ROS) has been 
demonstrated in numerous studies [97].  Although the mechanism by which Pb acts as 
a pro-oxidant is not fully understood, it is due, at least in part, to direct inhibition of the 
heme biosynthetic pathway enzyme δ-aminolevulinic acid dehydratase (δ-ALAD).  
Inhibition of δ-ALAD leads to elevated levels of the enzyme’s substrate, δ-aminolevulinic 
acid (δ-ALA), a known pro-oxidant that stimulates ROS production, lipid peroxidation, 
oxidative stress and is present in the blood and urine of Pb-exposed individuals [148].  
Pb also directly inhibits glutathione reductase, and binds protein sulfhydryls, thereby 
contributing further to oxidative stress in cells and tissues.  Markers of oxidative stress 
can be detected in blood, RBCs, serum, and urine of Pb exposed individuals [97].  
Recent studies revealed a strong association of blood Pb with markers of oxidative 
stress in the general population, and suggested that oxidative stress should be 
considered in the development of Pb-mediated diseases, even among people with 
relatively low environmental exposure to Pb (i.e. <10 μg/dL) [142]. 
Pb-induced oxidative stress is relevant to my hypothesis that Pb exposure 
promotes the formation of diabetes.  Oxidative stress is thought to promote the diabetic 
state by direct effects on cellular signaling pathways that influence insulin signaling.  
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Subjects exposed to Pb have increased ROS production, oxidative stress induction and 
elevated concentrations of δ-ALA in their blood and urine [120, 149-151].  One 
proposed mechanism is that ROS activate intracellular signaling through JNK/SAPK, 
p38 MAPK and NF-κB.  JNK activation results in serine phosphorylation and inhibition of 
IRS (Insulin Receptor Substrate) 1 and 2.  IRS1 and IRS2 are required for downstream 
signaling through additional serine/threonine kinases and their phosphorylation by JNK 
results in decreased insulin signaling and insulin resistance (for a review see [57]). 
 
2.5.3 – Previous Studies on the Effect of Pb on Metabolic Parameters in Rodents 
Although there is little recent work that addresses the effect of Pb on metabolism 
in animal models, three papers published in the 1970s and 80s suggested that Pb 
exposure could induce hepatic insulin resistance in rats.  Singhal et al. [152] reported 
that male rats treated with Pb acetate for 45 days (IP injection), showed a dose-
dependent increase in amounts of the gluconeogenic enzymes PEPCK and G6Pase in 
the liver.  Consistent with these Pb-induced increases in gluconeogenic gene 
expression, this study also reported a significant, dose-responsive increase in fasting 
blood glucose.  A similar finding was reported by Stevenson et al. in young female rats 
exposed to 20, 40 or 80 ppm Pb for 56 days in drinking water [153].  These animals also 
showed a Pb dose-responsive increase in PEPCK and G6Pase enzyme levels in the 
liver and significantly elevated fasting blood glucose.  Finally, Whittle et al. 
demonstrated that even small increases in blood lead levels from a control level of 
7.9±1.4 µg/dL to 13.8±1.3 μg/dL, for 42 days caused a significant increase in expression 
of hepatic gluconeogenic enzymes in rats [154].  
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When taken together, these data suggest an interesting possibility that Pb 
exposure induces hepatic gluconeogenic gene expression, which would contribute to 
elevated blood glucose levels.  However, these studies are somewhat dated and limited 
in scope - they did not include direct measurements of gene expression, and examined 
only minimal physiological parameters related to diabetes.  Updated techniques may 
also allow for the investigation of the molecular mechanism behind the deleterious 
effects of Pb. 
  
2.5.4 – The Potential Link Between Pb and Rev-erb-α 
Emerging evidence indicates that components of the circadian clock machinery 
can regulate expression of metabolic genes, including PEPCK, G6Pase and PGC1-α 
[155].  This evidence was further support by data gathered from mice with mutated 
Clock genes showing abnormal gluconeogenic gene expression [156-158].  However, 
the mechanism that links metabolic gene expression to circadian clock rhythms remains 
poorly understood.  
Recently, studies have shown that heme functions as an endogenous ligand for 
the orphan nuclear receptor Rev-erb-α (NR1D1), a known component of the circadian 
clock machinery [159].  Rev-erb-α is highly expressed in multiple tissues including liver, 
and functions as a heme-dependent transcriptional repressor [160-163].  Heme binding 
to Rev-erb-α suppresses the transcription of Rev-erb-α target genes including PEPCK, 
G6Pase and PGC1-α [155, 157, 158, 161, 162]. Thus, in the absence of heme, the 
gluconeogenic program is elevated [132].  The well described effect of Pb in the 
inhibition of heme biosynthetic enzymes [164-167] (described above) raises the 
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possibility that Pb exposure will contribute to elevated gluconeogenesis by reducing the 
suppressive effect of Rev-erb-α on gluconeogenic gene expression.  
 
2.5.5 – Hypotheses and Aims of Pb Project 
The overall goal of the Pb portion of my PhD project is to fully characterize the 
effect of Pb exposure on diabetes risk in metabolically stressed (obese) rodents, and to 
identify the molecular and cellular mechanisms by which it affects metabolic balance.  
The specific goals were to establish in vivo and in vitro models to study the 
physiological and molecular mechanisms by which Pb affects insulin sensitivity and 
glucose homeostasis.  This was an initial step in a broader research objective to 
determine if there is a cooperative interaction between environmental toxicant exposure 
and additional stressors from the physical and social environment that promote 
metabolic instability and disease.  
Together, these ideas formed the underlying hypothesis of my project, that in 
combination with metabolic stresses like obesity, Pb exposure increases diabetes 
susceptibility and severity.  The work was divided into two specific aims: (1) 
Characterize the extent to which Pb exposure promotes diabetes in two well-established 
rodent models of metabolic disease (Zucker Diabetic Fatty [ZDF] rats and human Islet 
Amyloid Polypeptide [hIAPP] transgenic mice) and determine the dependence of Pb-
induced diabetes on obesity and diet composition, (2) Characterize the mechanism by 
which Pb alters hepatic insulin sensitivity and gluconeogenesis.  
 Data generated from this work could have a significant impact on how we view 
the interaction of environmental toxicants with other behavioral and lifestyle stressors in 
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humans, and may provide the impetus to carry out epidemiologic studies to assess the 
risks of toxicant exposure in metabolically & nutritionally stressed populations. If such a 
link was observed in the human population, the animal models developed here may 
prove useful in developing therapies to reduce the deleterious effects of Pb exposure. 
Finally, the model systems established in this study will be of general utility for research 
on the interaction of other environmental toxicants and metabolically stressed 
individuals.   
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Chapter 3 – Materials and Methods 
3.1 – Zucker Diabetic Fatty Rats  
Female Zucker Diabetic Fatty rats (ZDF-Leprfa/Crl; stock 370 (OBESE)) 6 weeks 
of age, were purchased from Charles River Laboratories, Portage, Michigan.  Animal 
protocol (#A 07-16-08) for ZDF rats was approved by the Institutional Animal Care and 
Use Committee at Wayne State University.  
Two groups (n=4) of female ZDF fa/fa rats were treated with 0.05% w/v Pb 
acetate (PbAc) in the drinking water, which has been previously determined to generate 
a blood lead level of approximately 40-50 g/dL in rats [154].  Control animals received 
equimolar acetate in drinking water in the form of Na acetate (NaAc).   
Animals were housed on paper bedding for the duration of the study because 
animals can ingest corncob bedding during a fast, which can alter fasting blood glucose 
measures.  All animals were fed a standard chow diet (Purina 5008) from weeks 0 – 20, 
then switched to a high fat diet (RD 13004, 45% calories from fat diet, Research Diets, 
Inc.) from week 20 through termination (week 25).  Food and water were offered ad lib.  
Body weights and food consumption were measured weekly.  Food consumption was 
assessed by weighing the amount of food provided at the beginning of each week and 
subtracting the amount remaining at the end of the week.  While this method is not as 
accurate a measure of food consumption as would be obtained in a metabolic cage, it 
can reveal gross differences in nutritional intake. 
Fasting blood glucose (FBG) measures were obtained from whole blood using a 
Hemocue glucometer at weekly intervals (from the saphenous vein) after a 6 hour fast 
beginning at 4:00 am, until week 20 (start of high fat diet) when they were taken bi-
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weekly.  After the fasting blood glucose measurement was completed, a total of 400µL 
of blood was collected and mixed with 3.73µL of 0.5M EDTA, to attain a final 
concentration of 4.67mM EDTA per sample, placed on ice immediately and spun in 4°C 
centrifuge at 8,500g for 20 minutes.  Plasma was removed from packed RBCs and 
placed into new 0.5mL centrifuge tube in 25µL aliquots.  Both plasma and packed RBCs 
were place into storage at -80°C to be utilized for further metabolic measures (See 
Table 2.1 for a list of metabolic measures).   
Oral glucose tolerance tests (OGTTs) were conducted on each animal once 
every four weeks after a 6 hour fast beginning at 4:00 am.  Animals were given a bolus 
of 50% glucose equivalent to 2mg/g body weight, by oral gavage and blood glucose 
was measured using a Hemocue glucometer from 5μL of blood removed from the 
saphenous vein.  Time points were at 0 (prior to glucose bolus), 15, 30, 60 and 120 
minutes.   
Blood Pb levels in these samples were determined using standard assay 
protocols for measuring patient blood Pb levels at Detroit Medical Center University 
Laboratories by atomic absorption spectrometry. Packed red blood cells were 
resuspended to a final volume of 2mL in 0.9% physiological saline and measured on a 
Hitachi Z-2000 with Zeeman background correction.  
Animals were sacrifice at 25 weeks following a 6 hour fast/ 2 hour re-feeding 
protocol by CO2 asphyxiation and exsanguination by cardiac puncture.  Relevant 
tissues were removed, subdivided and placed in 4% buffered formalin at 4ºC, flash-
frozen or frozen in OTC (See Table 2.1 for a list of tissues).   
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3.2 – hIAPP Transgenic Mice 
Dr. Steven E. Kahn (Dept. of Veterans Affairs, Puget Sound Health Care System, 
Seattle, WA) generously supplied hIAPP transgenic male C57 Black 6 (C57Bl6) mice 
[168].  Females, 5-6 weeks old C57Bl/6J mice (stock no. 000664) and males, 6 weeks 
old DBA/2J (stock no. 000671) were purchased from Jackson Laboratories (Bar Harbor, 
ME).  Animal protocol (#A 08-15-10) for hIAPP mice was approved by the Institutional 
Animal Care and Use Committee at Wayne State University.  
Four hIAPP transgenic male C57Bl6 mice were bred with four female C57Bl/6J 
mice.  Female progeny were weaned at 3 weeks of age, tail-clipped for genotyping and 
ear notched for identification.  Female progeny found to be transgene positive were then 
bred to male DBA/2J mice.  DBA/2J background was utilized to provide a mouse model 
with increased insulin secretion, as insulin and islet amyloid polypeptide (IAPP) are co-
secreted this model was expected to experience increased amyloid plaque formation 
(discussed further in Chapter 6).  Male progeny were weaned at 3 weeks of age, tail-
clipped for genotyping and ear notched for identification.  Transgenic male progeny 
were separated and utilized for this study as previous studies observed a negative 
influence of estrogen on expression of the hIAPP transgene [169, 170] .  Breeding and 
genotyping were conducted in the laboratory of Dr. Paul Stemmer.  
Four groups of male hIAPP mice were established.  Two groups (n=16) were 
treated with 0.02% w/v PbAc (“high treated”) or equimolar NaAc (“high control”) in the 
drinking water.  The other two groups (n=12) were treated with 0.005% w/v PbAc (“low 
treated”) or equimolar NaAc (“low control”) in the drinking water.  Animals began PbAc 
or NaAc treatment at 10 weeks of age. 
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Animals were housed on paper bedding for the duration of the study because 
animals can ingest corncob bedding during a fast, which can alter fasting blood glucose 
measures.  All animals were fed a standard chow diet (Purina 5009) until weaned, then 
placed on a high fat chow diet (Autoclavable Mouse Breeder Diet 5021, Purina) 
containing 9% fat w/w (45% calories from fat) through termination (week 45).  Food and 
water were offered ad lib.  Body weights and food consumption were measured weekly. 
Food consumption was assessed by weighing the amount of food provided at the 
beginning of each week and subtracting the amount remaining at the end of the week.  
While this method is not as accurate a measure of food consumption as would be 
obtained in a metabolic cage, it can reveal gross differences in nutritional intake. 
Fasting blood glucose (FBG) levels were measured with a Hemocue glucometer 
from whole blood obtained at bi-weekly intervals (from the saphenous vein) after an 8 
hour fast beginning at 8:00 pm.  A total of 200µL of blood was collected and mixed with 
18.6µL of 0.05M EDTA to attain a final concentration of 4.67mM EDTA per sample and 
placed on ice immediately.  A 20µL aliquot of whole blood was separated for blood Pb 
level measurements and the remaining sample was spun in 4°C centrifuge at 2,500g for 
20 minutes as soon as possible.  Plasma was removed from packed RBCs and placed 
into new 0.5mL centrifuge tubes in 25µL aliquots.  Both plasma and packed RBCs were 
place into storage at -80°C to be utilized for further metabolic measures (See Table 
2.1).   
Oral glucose tolerance tests (OGTTs) were conducted on each animal, to 
establish baseline (time 0) glucose tolerance and at 6 months and 9 months of 
treatment after an 8 hour fast begun at 8:00 pm.  Animals were given a solution of 30% 
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glucose equivalent to 1.5mg/g body weight, administered as a bolus via balled gavage 
needle.  Blood glucose was measured using a Hemocue glucometer from 5μL of whole 
blood removed from the saphenous vein.  Time points were 0 (prior to glucose bolus), 
15, 30, 60 and 120 minutes.   
Blood Pb levels were assessed by Dr. Paul Stemmer and Steven Jones using 
the ICP-MS facilities in the Biochemistry Department at Wayne State University School 
of Medicine.   See section 3.5 below for specific protocol.  
Sacrifice at 45 weeks was by CO2 asphyxiation followed by cervical dislocation 
and exsanguination by cardiac puncture.  Relevant tissues were removed by sterile 
technique, washed with a solution of ice cold PBS (1x) plus 0.01M EDTA, subdivided, 
then either placed in 4% buffered formalin at 4°C, freeze-clamped or flash-frozen in 
OTC (See Table 2.1 for a list of tissues).   
Table 2.1 – Post-Termination Testing and Tissue Protocols 
Blood parameters   
Blood Pb levels 
Termination (rats) 
Biweekly (20µl, mice) 
DMC-UHL (packed RBCs) 
ICP-MS facility at WSU SOM (whole blood) 
Fasting blood glucose Weekly (4 µl) Glucometer (Hemocue) from whole blood 
Insulin Weekly (20 µl) Elisa (Millipore) 
Glucose tolerance (OGTT) 
Every 4 weeks (rats) 
0, 6 mo, 9 mo (mice) 
 
Glucometer (Hemocue) from whole blood 
Liver Tissue Parameters  
Liver histology At termination 
H & E, Masson’s Trichrome, Periodic Acid 
Schiff (fixed sections) 
Pancreatic histology At termination 
H & E, Masson’s Trichrome, Aldehyde 
Fuchsin, Congo Red (mice only)  (fixed 
sections) 
Triglyceride content At termination TG assay (kit from Cayman Chemicals) 
PEPCK, G6Pase, PGC1-  At termination qRT-PCR and western blots; from frozen liver 
Additional tissue samples for future analysis  
Liver samples for RNA profiling  At termination From frozen liver tissue  
Pancreas At termination Frozen in OTC for histology 
Skeletal Muscle (gastroc. & soleus) At termination Flash- frozen for RNA and protein analysis  
Adipose: subQ (inguinal), abdominal (retroperitoneal) At termination Flash-frozen 
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3.3 – Genotyping 
 Genotyping of hIAPP mice was done using DNA extracted from tail clip, using a 
protocol provided by Dr. Rebecca L. Hull’s laboratory (see reference [168]) and the 
previously published protocol by Laird et.al. [171].  Briefly, 0.5 cm of clipped mouse tail 
was digested with protease overnight, and DNA was ethanol precipitated from the clear 
supernatant after centrifugation.  Genotyping was carried out by Ms. NamHee Shin in 
Dr. Paul Stemmer’s lab. 
 
3.4 – Tissue Processing and Histological Staining  
  Tissues were fixed with 4% buffered formalin at 4°C; paraffin embedded, sliced in 
5μm sections, affixed to glass slides and allowed to dry.  Slides were then stained with 
Hematoxylin and Eosin, Aldehyde Fuchsin, Periodic Acid-Schiff, Congo Red or 
Masson’s Trichrome, all histological supplies were purchased from American 
MasterTech Supplies. 
 
3.4.1 – Deparaffinization and Dehydration 
 To remove paraffin prior to staining, slides were put through 2 changes of 100% 
Xylene for 3 minutes each, followed by 2 changes of 100% EtOH for 3 minutes each, 2 
changes of 95% EtOH for 3 minutes each, one change of 75% EtOH for 3 minutes, one 
change of 50% EtOH for 3 minutes and running tap water for 1 minute.  Slides were 
then treated with the staining protocol of choice followed by dehydration and mounting. 
 To dehydrate after conclusion of staining, slides were dipped into 95% EtOH, 
followed by 3 changes of 100% EtOH, once into 1:1 100% EtOH:100% Xylene and 2 
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changes of 100% Xylene.  Coverslips were mounted with ClearMount (American 
MasterTech) and allowed to dry for 72 hours undisturbed. 
 
3.4.2 – Hematoxylin and Eosin Staining 
 After deparaffinization, the American MasterTech protocol for Harris’ Hematoxylin 
and Eosin (Item# KTHNEPT) procedure was followed.  Both pancreas and liver slides 
were placed in Harris’ Hematoxylin for 5 minutes followed by running water rinse for 1 
minute.  Slides were then dipped into Differentiating Solution 3 times, followed by 
running water rinse for 1 minute.  Slides were placed in Bluing Solution for 35 seconds, 
rinsed in running water for 3 minutes then moved to 70% EtOH for 1 minute.  After 60 
seconds in Eosin Y Stain, slides were dehydrated, coverslips mounted and dried. 
 
3.4.3 – Aldehyde Fuchsin Staining 
After deparaffinization, the American MasterTech protocol for Aldehyde Fuchsin 
(Item# STAFU) procedure was followed.  Pancreas sections were placed in Aldehyde 
Fuchsin Stain for 2 hours, rinsed with 70% EtOH, placed in Light Green Counterstain for 
3 minutes then dehydrated, coverslips mounted and dried. 
 
3.4.4 – Periodic Acid-Schiff Staining 
After deparaffinization, the American MasterTech protocol for Periodic Acid-Schiff 
(Item# KTPAS) procedure was followed.  Liver sections were placed in 0.5% Periodic 
Acid for 7 minutes, rinsed quickly in distilled water then placed in Schiff’s Solution for 15 
minutes.  Slides were removed from Schiff’s Solution, rinsed in running water for 5 
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minutes, placed in Modified Mayer’s Hematoxylin for 2 minutes then rinsed in running 
water for 3 minutes.  Slides were then placed in to Light Green Counterstain for 10 
minutes, rinsed with 70% EtOH, dehydrated, coverslips mounted and dried. 
 
3.4.5 – Congo Red Staining 
After deparaffinization, the American MasterTech protocol for Congo Red (Item# 
KTCRE) procedure was followed.  Pancreas sections from hIAPP mice were placed in 
Congo Red Amyloid Stain for 2 hours, differentiated in 1% Sodium Hydroxide for 30 
seconds then rinsed in running water for 5 minutes.  Slides were then placed in to 
Modified Mayer’s Hematoxylin for 3 minutes, rinsed in running water for 1 minute, 
dehydrated, coverslips mounted and dried. 
 
3.4.6 – Masson’s Trichrome Staining 
After deparaffinization, the American MasterTech protocol for Masson’s 
Trichrome (Item# KTMTR) procedure was followed.  Pancreas and liver sections were 
placed in to Bouin’s Fluid and left overnight at room temperature.  The following day, 
they were left in running tap water until the tissue was colorless.  The slides were then 
placed into Weigert’s Hematoxylin for 5 minutes, rinsed in running water, placed in 
Biebrich Scarlet-Acid Fuchsin for 15 minutes and rinsed in distilled water.  They were 
placed into Phosphomolybdic/Phosphotungstic Acid for 15 minutes, then moved directly 
to Aniline Blue Stain for 10 minutes, rinsed in distilled water, placed in 1% Acetic Acid 
for 5 minutes, dehydrated, coverslips mounted and dried. 
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3.5 – Blood Pb Analyses 
 The protocol for blood Pb analyses was designed and carried out by Steven 
Jones, under the supervision of Dr. Paul Stemmer using the ICP-MS facilities in the 
Biochemistry Department at Wayne State University School of Medicine. 
Whole blood was collected from the saphenous vein and 20µL transferred to 
Eppendorf tubes and stored at -80C.  Samples were diluted with two volumes of 0.1% 
TritonX-100 added to the storage tube to ensure the protein was dissolved.  The clear 
samples then were further diluted with 17 volumes of 2% nitric acid spiked with 1 ppb 
rhenium (Re) for a final dilution of 20 fold.  Solutions were clear of obvious precipitates 
prior to addition of the nitric acid and proteins that were soluble in the triton solution 
precipitated upon the addition of the nitric acid.  The precipitated protein samples were 
incubated with the nitric acid for 24 hours then diluted for analysis.  
 Precipitates were pelleted by centrifugation and supernatants removed to a fresh 
tube.  Samples from animals that had not received Pb were diluted 3 fold while samples 
from Pb-treated animals were diluted 20 fold for a final dilution of 60 or 400 fold 
respectively.  Standards containing 0, 0.1, 0.3, 0.5, 0.8 and 1.0 ppb Pb in 2% nitric acid 
with 1 ppb rhenium were run before and after analysis of the samples.  The analysis 
was carried out using a PerkinElmer SCI EX ICP-MS (ELAN 9000).  The Pb and Re 
standards were purchased from Acros Organics.  The Pb was 2% in HNO3 and the Re 
was 1 mg/ml in water. 
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3.6 – Microscopy 
Histological imaging was completed utilizing a Leica D4000b Bright-field 
Microscope (Fisher Scientific) with Leica Digital Imaging Software (Fisher Scientific) 
housed at the Wayne State University Department of Anatomy and Cell Biology Imaging 
and Histopathology Core.  
 
3.6 – Triglyceride Assay 
Triglyceride Colorimetric Assay Kit (Item# 10010303, Cayman Chemicals) was 
used according to manufacturer’s instructions to assess tissue triglyceride levels.  
Briefly, 350mg of liver tissue from both ZDF rats and hIAPP mice was homogenized in 
1x Standard Diluent Assay Reagent, centrifuged at 10,000g and 4ºC, supernatant 
transferred to new tubes and stored on ice.  Samples were diluted 1:9 in Standard 
Diluent Assay Reagent (per protocol recommendations for tissue samples).  10µL per 
sample were loaded in duplicate and read at 540nm absorbance on VersaMax plate 
reader with SoftMax Pro 3.0 software (Molecular Devices).  Regression analysis of data 
was completed with GraphPad Prism 5. 
 
3.7 – Insulin ELISA 
Rat/Mouse Insulin ELISA Kit (Catalog# EZRMI-13K, EMD Millipore) was used 
according to manufacturer’s instructions to assess plasma insulin levels in both ZDF 
rats and hIAPP mice.  Briefly, frozen plasma samples from both ZDF rats and hIAPP 
mice were thawed, centrifuged at 2,500g at 4ºC, and the supernatants transferred to 
new tubes and stored on ice.  Duplicate 20µL samples were loaded into the prepared 
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96-well plate and combined with 80μL of Detection Antibody and allowed to incubate for 
2 hours.  After the incubation, the plate was washed, 100μL of Enzyme Solution added 
and incubated for 30 minutes.  After a series of 6 final washes, 100μL of Substrate 
Solution was added, followed by 100μl of Stop Solution.  The samples were then read at 
both 450nm and 590nm absorbance on VersaMax plate reader with SoftMax Pro 3.0 
software (Molecular Devices).  Regression analysis of data was completed with 
GraphPad Prism 5. 
 
3.8 – Cell Culture 
Primary rat hepatocytes (PRH) were obtained from Wayne State University’s 
Institute for Environmental Health Sciences Cell Culture Core.  PRH cells were plated at 
a density of 9 x 105 cells per well on collagen-coated (Rat tail collagenase, Invitrogen) 
6-well plates (Denville), in 10nM insulin-containing serum-free DMEM (HyClone) and 
allowed to recover overnight.  PRH cells were changed to insulin-free DMEM 2 hours 
prior to initiation of treatment protocols.   
Human hepatoma (HepG2) cells were cultured in 100mm dishes with high 
glucose DMEM (HyClone), supplemented with 10% FBS and 1% (v/v) 
penicillin/streptomycin.  HepG2 cells were plated at a density of 1 x 105 cell per well in 
6-well plates for gene expression experiments. 
FAO rat hepatoma cells, cultured in RPMI 1640 (Invitrogen) supplemented with 
10% FBS and 1% (v/v) penicillin/streptomycin.  FAO cells were plated at a density of 4.5 
x 105 cell per well in 6-well plates for gene expression experiments and 7.75 x 105 in 
60mm dishes for western blot experiments.   
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H4IIe rat hepatoma cells, cultured in high glucose DMEM (HyClone) 
supplemented with 5% FBS, 5% BCS and 1% (v/v) penicillin/streptomycin.  H4IIe cells 
were plated at a density of 6 x 104 cell per well in 6-well plates for gene expression 
experiments.  All cell cultures were maintained at 37ºC with a 5% CO2 atmosphere. 
 
3.9 – Western Blotting 
Cells were harvested with RIPA buffer, sonicated and cleared (centrifuged for 30 
minutes at 13,000g and 4°C). SDS-PAGE gels (pre-cast, Pierce) were loaded with 50µg 
protein per lane, one lane with 5uL Easy-Run REC-pre-stained marker (Fisher 
Scientific) and run for 1 hour at 40mA.  Transfer to nitrocellulose membrane was carried 
out overnight at 4ºC and 40mA in a Bio-Rad Mini Protean 3 transfer device.  
Nitrocellulose membranes were removed from transfer apparatus, Ponceau stained to 
confirm transfer of proteins, washed with TBS-T, blocked with 5% milk in TBS-T for 2 
hours followed by overnight incubation with phospho-AMPKSer79, phospho-ACCThr172 
(1:1000 in 5% BSA in TBS), total-AMPK or total-ACC (1:1000 in 5% BSA in TBS-T) 
antibodies (Cell Signaling Technologies).  After 3 washes in 1x TBS-T buffer, 
membranes were incubated with goat-anti-rabbit secondary antibody (1:1000 in 5% milk 
in TBS-T, Cell Signaling Technologies) at room temperature for 1 hour.  TBS-T was 
utilized for washes and ECL (Pierce) was utilized for chemiluminescence.  Membranes 
were stripped, re-blocked and incubated for loading control with GAPDH. 
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3.10 – Gene Expression Analyses 
3.10.1 – In Vivo Gene Expression  
 Total RNA was extracted a small piece of flash-frozen liver tissue using 
SpinSmart RNA Purification System with on-column tissue homogenizer kit (CM-610-
50, Denville Scientific). RNA quality and quantity was assessed by Nanodrop 
absorbance at 260/280 (Thermo Scientific) and mRNA was reverse-transcribed using 
High-Capacity cDNA Reverse Transcription Kit (Applied BioSystems).  A total of 100ng 
of cDNA was analyzed in a 20µL qRT-PCR reaction (TrueAmp SYBR Green, Smart 
Bioscience, Inc.) with 300 nM of primers.  Gene expression data were normalized to the 
house keeping gene peptidylprolyl isomerase A (PPIA) using the 2-delta-delta C(T) 
method (2-ΔΔCt) described by Livak and Schmittgen [172].  Sequences for primers 
used for qRT-PCR are listed in Table 2.2.   
 
3.10.2 – In Vitro Gene Expression 
Cells were washed with cold PBS after removal of media, lysed with direct 
application of Tri reagent (Sigma) and placed on ice. Total RNA was extracted from cell 
lysates, mRNA quality and quantity was assessed by Nanodrop absorbance at 260/280 
Table 2.2 – Primer Sequences Used for qRT-PCR 
 Forward (5’-3’) Reverse (5’-3’) 
hIAPP Mouse Primers  
mG6Pase 5’-CTGTCTGTCCCGGATCTACC-3’ 5’-GCGCGAAACCAAACAAGAAG-3’ 
mPEPCK 5’-AAGCGGATATGGTGGGAACT-3’ 5’-CTGCGGCCAGGTATTTCTTC-3’ 
mPGC1-α 5’-ACGCGGACAGAATTGAGAGA-3’ 5’-GTTTCGTTCGACCTGCGTAA-3’ 
mPPIA 5’-GGTCCTGGCATCTTGTCCAT-3’ 5’-ATGCCTTCTTTCACCTTCCCA-3’ 
   
ZDF Rat Primers  
 Forward (5’-3’) Reverse (5’-3’) 
rG6Pase 5’-TGAATCACTTCCGGTCTCCTGTCC-3’ 5’-TCCCGATCCTTCCTTCTCTTCCTAG-3’ 
rPEPCK 5’-GGGGTGCATGAAAGGCCGCA-3’ 5’-ATCCGCATGCTGGCCACCAC-3’ 
rPGC1-α 5’-GAGAGGCAGAAGCAGAAAGCAATTG-3’ 5’-CATCATCCCGCAGATTTACGGTG-3’ 
rPPIA 5’-CGGCTGATGGCGAGCCCTTG-3’ 5’-GCCAAATCCTTTCTCCCCAGTGC-3’ 
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(Thermo Scientific) and mRNA was reverse-transcribed using High-Capacity cDNA 
Reverse Transcription Kit (Applied BioSystems). Gene expression was analyzed by 
semi-quantitative PCR using conditions optimized for each individual primer set. A total 
100ng of cDNA, 10nM dNTPs (Denville), 1x Choice Taq (Denville) and 200 nM of gene-
specific primers (Integrated DNA Technologies, Inc.) were analyzed in a 20µL reaction 
(MyCycler, Bio-Rad). Each primer was run for a specific number of cycles: PEPCK (23 
cycles) and PPIA (23 cycles). Primers were designed to span exon junctions to 
minimize signal from potential genomic DNA contamination. Final PCR products were 
run on a 1.5% agarose gel (0.5µg/mL EtBr) in 1x TAE at 130mV for 80 minutes and 
imaged with a ChemiDoc XRS (Bio-Rad). Band densities were analyzed using the 
Image J software program and a specific sized selection box that limited the number of 
pixels were analyzed. Gene expression data were normalized to the house keeping 
gene PPIA.  Primer sequences used for semi-quantitative PCR are listed in Table 2.3.  
 
3.11 – HOMA2-IR Analyses 
 Homeostatic Model Assessment 2 (HOMA2-IR) calculator was accessed on 30 
June 2013 from: http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/.  HOMA2-IR is a 
computer modeling program that calculates a corrected nonlinear estimation of insulin 
resistance (IR) and percent beta-cell function (% β-cell function).  A number of empirical 
equations (nonlinear) are utilized by the HOMA2-IR computer program to predict 
numerical values from paired fasting blood glucose and insulin samples.  Paired fasting 
Table 2.3 – Primer Sequences Used for Semi-Quantitative PCR 
Forward (5’-3’) Reverse (5’-3’) 
rPEPCK:  5’-GCAGGCTGGCTAAGGAGGAA-3’ 5’-GGCCAGGTTGGTTTTCCCAC-3’ 
rPPIA:      5’-GTCGCGTCTGCTTCGAGCTGTTTG-3’ 5’-GTGTGAAGTCACCACCCTGGCACA-3’ 
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blood glucose and insulin measurements from weeks 0, 14, 26, 40 and 45 were 
converted to mmol/L and pmol/L, respectively.  Data are estimated numerical values for 
the calculations of IR and % β-cell function.  
 
3.12 – Statistical Analyses  
Statistical analyses, given in detail in figure legends, were performed with 
GraphPad Prism 5 and SPSS.  Data are presented as mean ± SEM.  Statistical 
significance between two groups was determined by unpaired t-test.  Comparison 
among groups was performed using two-way repeated measures ANOVA or two-way 
mixed-design ANOVA and corrected for violation of sphericity with the Greenhouse-
Geisser epsilon. 
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Chapter 4 – Dioxins 
4.1 – Hypotheses and Aims of Dioxin Project 
It is clear that dioxins are a persistent environmental contaminant with the ability 
to influence glucose metabolism and possibly lead to alterations in diabetes 
susceptibility.  
Because of this possibility, the following hypotheses were formed: (1) Exposure 
to dioxin alters hepatic gluconeogenic gene expression. (2) Dioxin-mediated AMPK 
activation contributes to the suppression of hepatic glucose production. These 
hypotheses were tested by two specific aims: (1) Characterize the effect of dioxin on 
hepatic gluconeogenic gene expression. (2) Determine the molecular mechanism(s) by 
which dioxins alter PEPCK gene expression. 
 
4.2 – Characterize the Effect of Dioxin on Hepatic Gluconeogenic Gene 
Expression 
As described in the background section, dioxin exposure in humans has been 
linked to changes in diabetes-related metabolic parameters [35, 36, 45, 138, 173]. 
However, its specific effect on hepatic glucose production (a key element in whole-body 
Fig. 4.1 – Experimental paradigm utilized for all gene expression studies.  
Cells were plated at t = -24 hours and changed to insulin-free media when 18 hour treatment was 
begun at t = 0, 6 hour treatment was begun at t = 12 and 3 hour treatment was begun at t = 15.  
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glucose homeostasis) is not clearly understood. To determine if dioxin affects 
expression of the key genes involved in hepatic glucose production, primary rat 
hepatocytes (PRH) and FAO rat hepatoma cells were treated with dioxin and mRNA 
levels of gluconeogenic genes (PEPCK and G6Pase) were measured.  Treatment times 
(Figure 4.1) and doses were established in a series of pilot optimization experiments 
(data not shown).  As seen in Figure 4.2, 10nM dioxin was sufficient to suppress both 
PEPCK and G6Pase by greater than 2-fold at 6 hours and by 4- and 10-fold 
respectively at 18 hours over the 3 hour vehicle control.  In contrast, expression of 
CYP1A1 (a known AhR-regulated dioxin target gene) was strongly stimulated by dioxin 
treatment, confirming the presence of dioxin in the cells (Figure 4.2). These results 
demonstrate the ability of dioxin to suppress PEPCK and G6Pase, two key 
gluconeogenic genes involved in hepatic glucose homeostasis.  Results from FAO cells 
(data not shown) mirrored those obtained from PRH cells. 
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4.3 – Determine the Molecular Mechanism by Which Dioxin Alters PEPCK Gene 
Expression  
 
4.3.1 – Effect of AhR Inhibition on Dioxin-Mediated PEPCK Gene Suppression 
The effects of dioxin are primarily mediated by activation of the Aryl hydrocarbon 
receptor (AhR) [48-54]. To determine if the dioxin-mediated suppression of PEPCK 
gene expression is dependent on activation of AhR, a pharmacological antagonist of the 
AhR, PD168641 (3’-methoxy-4-nitroflavone) was utilized [174, 175].  PRH cells were 
pretreated with 1μM PD168641 for 15 minutes prior to addition of 1µM dex and 1mM 
Fig. 4.2 – Dioxin exposure leads to increased suppression of both PEPCK and G6Pase 
over time.   
PRH cells in insulin-free media were exposed to DMSO or 10nM dioxin as well as 1µM dex 
plus 1mM cAMP for 3, 6 and 18 hours and changes in gene expression were assessed by 
qRT-PCR. Data analyzed by students T test and are the means +/- SEM of three 
independent experiments, *p<0.05, **p<0.005. 
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cAMP and either DMSO or 10nM dioxin. Results demonstrated that PD168641 
significantly inhibited the AhR at 24 hours, as evidenced by the nearly complete 
suppression of the stimulatory effect of dioxin on CYP1A1 mRNA levels, in the presence 
of PD168641 (Figure 4.3, right panel). In contrast, the suppression of PEPCK and 
G6Pase gene expression was essentially unaffected by the presence of PD168641, 
demonstrating that activation of the AhR was not the mechanism whereby dioxin 
suppressed gluconeogenic gene expression.  
 
 
4.3.2 Dioxin is a Mild AMPK Activator 
Most of the effects of dioxins are mediated by activation of the AhR.  However, 
my findings and a previous study have suggested an alternative mechanism whereby 
dioxins may be suppressing PEPCK gene expression, via activation of AMPK [34].  
Fig. 4.3 – Effect of AhR inhibition on dioxin-mediated suppression of PEPCK gene 
expression.   
PRH cells were pre-treated with PD 168641 (AhR antagonist) for 15 minutes.  Cells were 
then subjected to treatment groups consisting of: Vehicle = DMSO, Dioxin = 1mM cAMP + 
1μM dex + 10nM dioxin, Dioxin + Antagonist = 1mM cAMP + 1μM dex + 10nM dioxin + 1µM 
PD 168641 for 24 hours.  Data are means of 2 independent experiments. 
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AMPK is activated by phosphorylation and is known to mediate a down regulation of 
PEPCK gene expression [176, 177]. AMPK can be pharmacologically activated in PRH 
and other hepatoma cell lines by the AMP analog, 5-aminoimidazole-4-carboxamide-1-
ß-D-ribofuranoside (AICAR) [178]. To determine if dioxin activates AMPK, (PRH) cells 
were exposed to either 50nM dioxin or 500µM AICAR for 1, 2 and 4 hours (see Figure 
4.4 for experimental time line) and then analyzed by western blot. Results demonstrated 
that AMPK is phosphorylated and mildly activated in the presence of 50nM dioxin at 1, 2 
and 4 hours (Figures 4.5 & 4.6).  Secondarily, a downstream target of AMPK, Acetyl 
CoA Carboxylase (ACC), is also phosphorylated in cells exposed to dioxin, causing it to 
be inactivated [179].  These data demonstrate that dioxin activates AMPK, and 
suggests that its effects on gluconeogenic gene expression are mediated by this 
mechanism. 
 
 
 
 
 
Fig. 4.4 – Experimental paradigm utilized for all protein expression studies.  
Cells were plated at t = -24 hours and changed to insulin-free media two hours prior to beginning 
dioxin exposure. Cells were treated with 1µM dex and 1mM cAMP and either 50nM dioxin or 
500µM AICAR. 
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Fig. 4.5 – Dioxin is a mild AMPK activator.   
Western blot showing changes in phosphorylation after dioxin or AICAR exposure.  
PRH cells treated for 1, 2 and 4 hours with either 50nM dioxin or 500µM AICAR. p-
ACC = phospho-ACC, t-ACC = total ACC, p-AMPK = phospho-AMPK, t-AMPK = total 
AMPK. 
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4.4 – Conclusions 
The effects of dioxins are primarily mediated by activation of the aryl hydrocarbon 
receptor, AhR [48-54].  However, my data (figures 4.5 and 4.6) and a previously 
published study have suggested an alternative mechanism whereby dioxin may be 
suppressing PEPCK and G6Pase gene expression, via activation of AMPK [34].  AMPK 
is a cellular energy-sensing protein that is activated when AMP levels within the cell 
become high [141].  AMPK can be artificially activated in primary rat hepatocytes and 
other hepatoma cell lines by the pharmacological reagent, 5-aminoimidazole-4-
carboxamide-1-ß -D-ribofuranoside (AICAR) resulting in AMPK phosphorylation.  Acetyl 
CoA Carboxylase (ACC) stimulates the conversion of Aceyl CoA to Malonyl CoA (MCA) 
Fig. 4.6 – Quantification of AMPK activation by dioxin.  
AICAR is a known AMPK activator. PRH cells treated for 1, 
2 and 4 hours with either 50nM dioxin or 500µM AICAR. 
There is a “nearly significant” (p = 0.0505) stimulation by 
dioxin observed at 2 hours. Data are the means +/- SEM of 
three independent experiments. 
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which is a substrate for fatty acid (FA) synthesis and a potent inhibitor of the 
mitochondrial FA transporter carnitine palmitoyltransferase 1 (CPT1) [180].  
Phosphorylated AMPK is known to phosphorylate and inactivate ACC, this leads to 
decreased fatty acid synthesis.  Phosphorylated AMPK is also known to cause 
suppression of PEPCK and G6Pase gene expression, which would reduce hepatic 
glucose production [178].  Hepatic glucose production regulation by AMPK has been 
attempted in the clinical setting with the anti-diabetic drug metformin [181, 182]; this 
drug has been proposed to lower hepatic glucose production in diabetic patients via 
AMPK activation [183, 184].  The ability of AMPK to suppress the key gluconeogenic 
genes PEPCK and G6Pase demonstrates its importance as a regulator of hepatic 
glucose production and as a potential or possible target of dioxin.   
We observed that dioxin treatment stimulated the AMPK signaling pathway 
(figures 4.5 and 4.6), which is known to have a suppressive effect on PEPCK gene 
expression [178].  The pharmacological reagent Compound C (6-[4-(2-Piperidin-1-yl-
ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo-[1,5-a]-pyrimidine) has been shown to inhibit 
AMPK activation and could be utilized to ascertain if the suppressive effects of dioxin on 
PEPCK and G6Pase gene expression are mediated via dioxin-induced AMPK 
phosphorylation [182, 185]. 
Previously published studies suggested that while dioxin exposure increased 
peripheral insulin resistance it did not appear to cause fasting hyperglycemia or 
elevated hepatic glucose output [35, 39, 42, 45-47].  In concordance with these findings 
we observed that dioxin treatment caused a strong suppression of the expression of 
genes for the key gluconeogenic enzymes PEPCK and G6Pase (figures 4.2 and 4.3).  
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However, the effects of dioxin in our in vitro system appear to be mediated 
independently of the AhR (figure 4.3).  There is a consensus among researchers that 
dioxin-induced toxicity, while primarily mediated via the AhR, may function via an AhR-
independent pathway [186-188].  A recently published study demonstrated the ability of 
dioxin to suppress expression of the checkpoint protein Mad2 in AhR-deficient mice, 
suggesting a novel dioxin-induced AhR-independent signaling mechanism at work 
[189].  Additionally, AhR-independent effects of dioxin-induced toxicity include the ability 
of dioxin to induce expression of several mouse glutathione S-transferase genes that do 
not contain xenobiotic response elements (XREs), previously thought to be a necessity 
in eliciting a dioxin response [190].  And several independent studies have shown that 
dioxin targets T cells via both AhR-dependent and AhR-independent mechanisms 
resulting in suppression of the immune system [191-196]. 
 While the effects on hepatic glucose production, AMPK and energy metabolism 
are not clearly understood, previous studies and my data suggest that, in addition to 
interacting with its well-characterized receptor AhR, dioxin may function in an AhR-
independent manner to target and activate the metabolic kinase, AMPK.  AMPK 
regulates a variety of metabolic pathways and its activation by an environmental 
toxicant would constitute a mechanistic link between toxicant exposure and the 
regulation of metabolism. 
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Chapter 5 – Lead Exposure Promotes Diabetes Development in Obese 
Rats 
 
As described in the background section, little recent work addresses the effect of 
Pb on metabolic parameters in vivo.  The data that do exist, when taken together, 
suggest that Pb exposure alters liver function, hepatic gluconeogenic gene expression 
and glycemia [152-154].  However, they do not address the potential pathological 
interactions between Pb exposure and concomitant risk factors such as obesity, which 
is strongly associated with diabetes and the metabolic syndrome [44].  The Pb-obesity 
interaction is a relevant issue in large sections of the US population where 
environmental stressors of over-nutrition (taking in more calories than the body needs) 
and an inactive or sedentary lifestyle are common and co-exist with exposure to 
persistent environmental toxicants, such as Pb. 
The overall goal of the in vivo portion of my PhD work is to characterize the effect 
of Pb exposure on diabetes risk in metabolically stressed (obese) rodents.   To explore 
the specific hypothesis that Pb exposure increases diabetes susceptibility in obese 
individuals, two well-established rodent models of obesity were utilized: the Zucker 
Diabetic Fatty (ZDF) rat and the high fat fed, human islet amyloid polypeptide (hIAPP), 
transgenic mouse (presented in Chapter 6).  The experimental approach is designed to 
reproduce, as far as possible, effects of Pb exposure in the human population, where 
obesity and diabetes risk factors are common.   
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5.1 – Zucker Diabetic Fatty (ZDF) Rat Model 
One of the standard rodent models used in diabetes research to study the 
physiology of obesity-related type 2 diabetes is the Zucker Diabetic Fatty (ZDF) rat. 
Originally derived from a colony of rats at Eli Lilly Research Laboratories and named 
after the scientists that discovered the fatty mutation, the ZDF (fa/fa) rat was established 
from a colony that had the diabetic characteristics of obesity and fasting hyperglycemia 
[197].  The genetic lesion that causes hyperphagia and obesity in ZDF rats is a mutation 
in the leptin receptor.  Rats homozygous for this mutation (fa/fa) will become obese 
when fed regular chow.  A specially formulated high fat diet leads to development of 
Type 2 diabetes in fa/fa animals.  ZDF rats that are heterozygous (fa/+) tend to be lean 
and are often utilized as a non-diabetic control.   
The diabetes phenotype differs in male vs. female ZDF rats.  There are several 
advantages in utilizing female ZDF rats instead of the more commonly used male ZDF 
rats.  Feeding commercially available rodent diets, such as Purina 5008, to female ZDF 
rats induces a prolonged insulin resistant but non-diabetic state.  However, when fed 
the RD13004 high fat diet from Research Diets, Inc., they develop fulminate diabetes 
within approximately 1 month [198].  The progression of the female ZDF toward 
fulminate diabetes on the RD13004 diet is very well characterized and highly 
reproducible.   
Unlike the male ZDF, the female possesses more robust β-cell compensation 
even though they share similar levels of insulin resistance.  The β-cell compensation 
allows for maintenance of blood insulin levels for a much longer time frame and extends 
the time course of diabetes development.  They can be initiated into this progressive 
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Fig. 5.1 – Experimental time frame for ZDF rats.  
Rats arrived and were allowed to acclimate for one week. Weekly fasting blood 
glucose draws and monthly oral glucose tolerance tests (OGTTs) were performed as 
indicated.  RD13004 high fat diet feeding was initiated at 20 weeks. 
pathway at 6 weeks and be maintained in this insulin resistant state for up to 25 weeks 
of age.  This large span of time provides an extended period in which these animals are 
obese, insulin resistant and non-diabetic, providing an excellent opportunity to observe 
subtle effects of Pb exposure on the rate of diabetes progression during the 
experimental time frame (Figure 5.1).   
 
 
 
 
 
 
 
 
5.2 – ZDF Experimental Setup 
The ZDF experiment consisted of two groups (n=4) of 6 week old female fa/fa 
rats, the characteristics of which were described in the previous paragraphs.  Rats 
arrived and were allowed one week to acclimate prior to initiation of experimental 
protocols.  One group was provided 0.05% w/v Pb acetate (PbAc) in drinking water (an 
amount previously determined to generate a blood lead level of approximately 40-50 
μg/dL in rats [154]).  The control group was provided an equimolar amount of NaAc in 
drinking water to balance the acetate intake of the two groups.  Animals were fed a 
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standard chow diet (Purina 5008) until week 20, when they were switched to the 
RD13004 high fat diet (45% calories from fat diet) from Research Diets, Inc.  Food and 
water were offered ad lib. 
Body weight and food intake were measured weekly, blood was drawn weekly 
from fasted animals for blood glucose level determination.  Oral glucose tolerance tests 
(OGTTs) were performed every 4 weeks.  After 25 weeks of exposure, animals were 
sacrificed by CO2 asphyxiation and exsanguination via aortic puncture.  Immediately 
preceding termination, rats were fasted for 6 hours and then allowed a 2 hour re-feeding 
period.  Pancreatic and liver tissues were removed and portions were placed in 4% 
buffered formalin at 4ºC, flash-frozen or frozen in OTC for histology and molecular 
analyses.  Additional endpoint measures included plasma insulin and liver triglycerides.   
  
5.3 – Basic Parameters of the ZDF Model 
Pb exposure did not affect body weight (Figure 5.2) or food intake (Figure 5.3). 
To assess blood Pb levels generated by 0.05% w/v PbAc in drinking water (an amount 
previously determined to generate a blood lead level of approximately 40-50 μg/dL in 
rats [154]), Pb levels in packed red blood cells were measured by atomic absorption 
spectrometry at Detroit Medical Center – University Laboratories.  The average blood 
Pb level of the Pb-treated rats, at termination, was determined to be 49µg/dL (Figure 
5.4).   The findings that there were no body weight or food intake differences suggest 
that there were no major effects of Pb on appetite or activity even at relatively high 
levels of exposure.  
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 Fig. 5.2 – Body weight measures for ZDF rats.  
There was no difference in body weight between groups. Data are means 
+/- SEM, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3. 
 
 
Fig. 5.3 – Food consumption measures for ZDF rats.  
There was no difference in food consumption between groups. Data are 
means, +/- SEM, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3. 
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5.4 – Pb Exposure Effects on Metabolic Parameters 
Elevated fasting blood glucose is one of the hallmarks of type 2 diabetes.  
Although female ZDF fa/fa rats fed a chow diet develop insulin resistance, they are able 
to maintain relatively normal blood glucose levels due to efficient compensation of 
insulin output by the endocrine pancreas.  However, as shown in Fig. 5.5, exposure to 
Pb induced a persistent fasting hyperglycemia starting at 10 weeks exposure, compared 
to control rats who maintained near normal levels of fasting blood glucose throughout 
the study.  Repeated measures ANOVA calculations demonstrated a significant 
deviation in fasting blood glucose levels between the Pb and control groups beginning 
at 8 weeks of exposure through termination. 
 
 
Fig. 5.4 – Blood Pb levels for ZDF rats at termination. 
ZDF rats treated with 0.05% w/v PbAc or equimolar NaAc 
in drinking water. Termination BLL average was 49µg/dL. 
Analysis completed by students T test.  Data are means 
with SEM, * p<0.05, Na n=4, Pb n=3. 
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Another hallmark of diabetes is glucose intolerance, the inability to clear 
postprandial glucose from the circulation.  Monthly OGTTs performed after an overnight 
fast showed a striking progressive glucose intolerance in Pb-exposed rats, but not in 
control rats (Figures 5.6 and 5.7).  The fasting hyperglycemia and glucose intolerance 
observed in the Pb treated animals clearly demonstrates that Pb exposure has a 
profound negative effect on glucose homeostasis in obese rats.  There are multiple 
mechanistic possibilities for how Pb might alter glucose metabolism, including reduced 
peripheral insulin sensitivity, defective glucose-mediated insulin secretion by the 
pancreas, and/or elevated hepatic glucose production. 
 
  
Fig. 5.5 – Pb exposure causes fasting hyperglycemia in obese rats. 
The Pb group started with lower fasting glucose levels (due to chance), but from week 8, 
their glucose levels rose above the control group. The high fat diet uncovers an elevated 
susceptibility to diabetes in the Pb group. Analysis completed by repeated measures 
ANOVA and corrected for violation of sphericity with the Greenhouse-Geisser epsilon 
demonstrated significant hyperglycemia in Pb group from week 8 through termination.  Data 
are means +/- SEM, *p<0.05, weeks 0-8: both groups n=4, Weeks 9-25: Na n=4, Pb n=3. 
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Fig. 5.6 – Pb exposure causes glucose intolerance. 
Oral glucose tolerance tests (OGTTs) in control (NaAc) and Pb-treated (PbAc) female ZDF 
fa/fa rats after exposure to Pb for 0 or 16 weeks. Both groups had similar glucose tolerance 
before Pb exposure, while at 16 weeks, the Pb exposed rats were glucose intolerant 
compared to control rats. Glucose tolerance at 16 weeks was significantly different by 
ANOVA, **p<0.005. Data are means, +/- SEM, before Pb exposure: n=4 both groups, 16 
Weeks: Na n=4, Pb n=3. 
 
 
Fig. 5.7 – Progressive glucose intolerance caused by Pb exposure. 
The area under the curve (AUC) was calculated for each of the OGTT assays 
performed on the ZDF rats. The data shows a progressive glucose intolerance in the 
Pb exposed rats, while the control rats maintained a similar glucose tolerance 
throughout the course of the study. Data are means, weeks 0-8: both groups n=4, 
weeks 12-20: Na n=4, Pb n=3. 
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To examine the possibility that Pb directly affects regulation of glucose 
production in the liver, changes in hepatic gluconeogenic gene expression in ZDF rats 
was examined.  Upon termination, mRNA was isolated from a small sample of flash-
frozen liver tissue.  Changes in gluconeogenic gene expression were quantified by two-
step qRT-PCR with sequence-specific primers for PEPCK, PGC1-α and PPIA.  As 
shown in Fig 5.8, these data revealed that expression of the hepatic PEPCK gene was 
elevated in Pb-exposed animals.  Elevated PGC1-α mRNA is consistent with the 
PEPCK results as PGC1-α functions as a transcriptional co-activator for this gene.  
Overall, the gene expression results are consistent with the possibility that the fasting 
hyperglycemia observed in the Pb-exposed animals is due, at least in part, to 
abnormally elevated hepatic glucose output.  It is important to note that the animals 
were sacrificed at termination after a fasting re-feeding protocol (described in methods), 
so that in this context, the elevated gluconeogenic gene expression could be related, at 
least in part, to a deficiency in the insulin-mediated suppression of gluconeogenic gene 
expression.  In other words, these findings may be indicative of hepatic insulin 
resistance.  
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To examine the possibility that Pb exposure affects pancreatic insulin production, 
insulin levels were determined in plasma samples from multiple time points throughout 
the study.  Insulin ELISA results from the ZDF rats show a mild decrease in blood 
insulin levels in the Pb-treated rats from approximately 8 weeks of treatment through 
termination (Figure 5.9).  While these findings are consistent with a potential defect in 
the ability of the pancreas to produce insulin, the differences between the control and 
treated groups were small and not statistically significant.  Insulin ELISA results from 
fasting/re-feeding termination samples showed no difference between the control and 
treated groups (data not shown).  Together these findings indicate that while there may 
be some pancreatic deficiency relative to the control group, Pb exposure did not cause 
pancreatic failure or a major defect in the ability of islets to produce insulin.  
 
Fig. 5.8 – Pb exposure induces gluconeogenic gene expression. 
Changes in gluconeogenic gene (mRNA) expression were quantified by qRT-
PCR with sequence-specific primers for PEPCK and PGC1-α. Data are means 
relative to housekeeping gene PPIA +/- SEM, presented on a log axis, Na n=4, 
Pb n=3. 
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A small sample of flash-frozen liver tissue was ground and analyzed for 
triglyceride content by colorimetric ELISA assay to determine lipid content.  Results 
revealed that the Pb-treated ZDF rats had accumulated significantly more triglycerides 
in their liver than the control animals (Figure 5.10).  The data demonstrates that Pb 
exposure promotes accumulation of triglycerides within the liver tissue consistent with 
the development of hepatic steatosis.   
 
 
 
 
 
Fig. 5.9 – Pb exposure does not affect insulin 
production. 
Plasma insulin levels measured by ELISA show 
decreased levels in Pb-treated rats from approximately 
week 8 forward.  Data are means +/- SEM, Weeks 0-8: 
both groups n=4, Weeks 12-20: Na n=4, Pb n=3. 
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5.5 – Pb Exposure Effects on Histological Parameters 
To determine if Pb exposure affected liver morphology, a portion of the liver from 
each animal was subjected to standard histological analyses.  Hematoxylin and eosin 
(H & E) staining demonstrated that both control and Pb-treated rats have normal hepatic 
lobule structure (Figures 5.11 and 5.12), showing that Pb does not affect gross liver 
morphology.   
 
 
 
 
 
Fig. 5.10 – Pb exposure causes increased triglyceride 
accumulation. Liver tissue triglycerides were measured 
by colorimetric assay.  Data are means +/- SEM, 
analyzed by students t test, **p < 0.005, Na n=4, Pb n=3. 
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Fig. 5.11 – Control ZDF Liver H & E.  
Normal hepatic lobular structure is intact. Magnification 5x, bar = 1mm. 
Fig. 5.12 – Pb-treated ZDF Liver H & E.   
Normal hepatic lobular structure is intact. Magnification 5x, bar = 1mm.  
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Having determined that Pb exposure did not alter hepatic morphology, I sought to 
determine if it had any effect on glycogen content or distribution.  Periodic Acid-Schiff 
stain is commonly utilized to detect glycogen in histological sections.  A specimen that is 
PAS-positive will show glycogen (carbohydrates) as pink/magenta to purple/red in color. 
PAS staining of prepared liver slides, while not quantitative, revealed that Pb exposure 
caused a generalized depletion of hepatic glycogen, as evidenced by the decreased 
level of PAS-positive staining in the Pb-treated liver slide (Figures 5.13 and 5.14).  
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Fig. 5.13 – Control ZDF Liver PAS.   
Note the numerous PAS-positive glycogen deposits (purple coloration) in the 
liver of the control rat.   Magnification 5x, bar = 1mm. 
Fig. 5.14 – Pb-Treated ZDF Liver PAS.   
Evidence of glycogen depletion after Pb exposure. Note the decrease in PAS-
positive staining in the liver of the Pb-treated rat. Magnification 5x, bar = 1mm. 
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To determine if Pb exposure affected pancreatic morphology, a portion of the 
pancreas from each animal was subjected to standard histological analyses.  While the 
quality of the specimens was not ideal due to the embedding technique utilized, H & E 
staining demonstrated that Pb exposure did have an effect on islet morphology.  Islets 
from control rats (n = 4) appeared normal, with a round shape and a well-defined border 
(Figure 5.15).  However, islets from Pb-treated rats (n = 3) appeared to be somewhat 
larger in size and did not display a well-defined border (Figure 5.16).  Overall, the 
subjective appearance of the islets from the Pb exposed animals suggested a general 
degradation of normal islet architecture, which is consistent with the possibility that 
these islets have at least a minor degree of compromised endocrinological function.  
Staining for specific hormones was not an option due to the poor quality of the 
specimens. 
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Fig. 5.15 – Control ZDF Pancreas H & E.   
Islets are lighter stained, round areas, denoted by the red arrows. Control 
animal islet physiology appears normal.  Magnification 5x, bar = 1mm. 
Fig. 5.16 – Pb-Treated ZDF Pancreas H&E.   
Islets are lighter stained areas, denoted by the red arrows. Note perimeter 
changes and damaged architecture of islets in Pb-treated animal, this islet 
physiology appears abnormal. Magnification 5x, bar = 1mm. 
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Noting the alterations in islet morphology in Pb-treated animals, I wanted to 
determine if Pb exposure caused an increased presence of β-cells in pancreatic islets.  
Aldehyde Fuchsin is commonly used to distinguish β-cells from α-cells and δ-cells within 
the islets of pancreatic tissue samples as β-cells stain a blue to violet or purple punctate 
in color.  Although these specimens are not ideal, and therefore the β-cells are not 
easily quantified, there appeared to be increased Aldehyde Fuchsin staining in Pb 
exposed samples (Figures 5.17 and 5.18).  These findings, while not striking, are 
suggestive of β-cell hyperplasia in the Pb-treated animals and are consistent with the 
apparent larger size of islets observed in the H&E stained sections. 
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Fig. 5.17 – Control ZDF Pancreas Aldehyde Fuchsin.  
Yellow arrows indicate Aldehyde Fuchsin-positive β-cells. Magnification 10x, 
bar = 200µm. 
Fig. 5.18 – Pb-Treated ZDF Pancreas Aldehyde Fuchsin.  
The appearance of a greater number of Aldehyde Fuchsin-positive β-cells 
(yellow arrows) is suggestive of a greater degree of β-cell hyperplasia in the 
Pb-treated animals. Magnification 10x, bar =200µm. 
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5.6 – Additional Histological Observations 
Liver tissue was examined for fibrosis with Masson’s Trichrome stain, but there 
was no discernible difference between the control and Pb-treated animals (data not 
shown).  Pancreatic tissue was also examined for fibrosis with Masson’s Trichrome 
Stain, and while there was some fibrosis present, there was no discernible difference in 
the degree of fibrosis between the control and Pb-treated groups (data not shown).   
 
5.7 – Discussion of ZDF Study 
It is clear from the data presented here, that Pb exposure promotes the 
development of diabetes in obese rats, specifically causing the development of fasting 
hyperglycemia and glucose intolerance.  Of additional interest is the observation that 
when the animals were switched to a diabetogenic high fat diet at week 20 the Pb-
exposed rats showed a dramatic increase in fasting hyperglycemia, suggesting that 
extended exposure to the toxicant made the animals more susceptible to the deleterious 
effects of the further metabolic stress of a high fat diet. These striking findings provide 
strong support for the hypothesis that, in metabolically stressed rodents, Pb exposure 
increases susceptibility to diabetes and promotes the progressive development of 
metabolic abnormalities. 
 Although many factors can contribute to fasting hyperglycemia, a major 
contributor is often elevated hepatic glucose output [199, 200].  In accordance with the 
possibility that Pb directly affects the regulation of glucose production in the liver, gene 
expression data revealed that PEPCK and PGC1-α expression were elevated in Pb-
exposed animals. These findings at the mRNA level are consistent with previously 
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published results from somewhat similar experiments with Pb exposed rats elevated 
activity levels of PEPCK were observed (described in more detail in the background 
section) [152-154].  The dysregulation of the insulin-mediated suppression of hepatic 
gluconeogenic gene expression could be a major contributor to the glucose intolerance 
observed in this animal study and suggests hepatic insulin resistance.  
 Consistent with this possibility is the observation of hepatic steatosis in the Pb-
treated animals.  Fatty liver is frequently observed in insulin resistant humans and 
animal models and is associated specifically with hepatic insulin resistance [201-203].  
The hepatic lipid accumulation in our animals may be secondary to the hyperglycemia 
we observed, which has been shown to be a “trigger” that stimulates de novo synthesis 
of hepatic lipids [204, 205].  Also consistent with Pb-induced metabolic dysfunction 
centered on the liver, is the observation that livers from Pb exposed rats were glycogen 
depleted (Figures 5.13 and 5.14).  Glycogen depletion has been associated with 
elevated fasting blood glucose [200, 206], and may also be consistent with hepatic 
insulin resistance. 
Examination of gross pancreatic morphology using H & E staining revealed Pb-
related disturbances in islet organization.  Control rat islets appeared normal, with a 
round shape and a reasonably definable border.  Pb-treated rat islets lacked the round 
shape seen in the control animals and had less well defined borders.  Although 
suggestive of pancreatic dysfunction, we did not observe a significant difference in 
blood insulin levels suggesting that these abnormalities were not severe enough to 
block β-cell compensation in these animals.  Beta-cell compensation in Pb-treated 
animals was confirmed by a greater prevalence of Aldehyde Fuchsin positive β-cells.  
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Our results do not rule out the possibility that Pb affects peripheral insulin 
resistance in these animals.  Unfortunately, a direct measurement of peripheral insulin 
sensitivity in intact animals is difficult and was beyond the technical scope of our lab and 
my thesis.  If there is peripheral insulin resistance in these animals, it would contribute 
to the observed hyperglycemia, which was present despite normal insulin levels. 
These data demonstrate for the first time that Pb promotes the development of 
Type 2 diabetes in a rat model of obesity.  I identified Pb-induced defects in both 
hepatic glucose output and in postprandial glucose clearance.  Both of these are insulin 
mediated processes and it seems likely that Pb is interfering in the insulin signaling 
pathway, at least in liver, and possibly also in muscle.  The data also identified key 
histological aspects of Pb-exposure, including islet abnormalities and increased β-cell 
compensation.   
A key question that the data do not address is if the pro-diabetic effect of Pb is 
dependent on obesity or other metabolic stresses.  The experiments conducted in the 
hIAPP transgenic mouse model (described in the next chapter) were designed to 
examine this possibility and to characterize the specific effects of Pb exposure in a high 
fat diet-induced rodent model of Type 2 diabetes.  The gene expression results are 
consistent with previously published animal studies and yield a potential molecular 
mechanism to be explored in vitro (described in Chapter 7).  
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Chapter 6 – Lead Exposure Causes Metabolic Abnormalities in a 
Humanized Mouse Model of Pancreatic Amyloidosis 
 
The Pb-obesity interaction is a relevant issue in large sections of the US 
population where environmental stressors of over-nutrition and an inactive sedentary 
lifestyle are common, and co-exist with exposure to persistent environmental toxicants, 
such as Pb. 
The overall goal of the in vivo portion of my PhD work is to characterize the effect 
of Pb exposure on diabetes risk in metabolically stressed (obese) rodents.   To explore 
the specific hypothesis that Pb exposure increases diabetes susceptibility in obese 
individuals, two well-established rodent models of obesity were utilized: the Zucker 
Diabetic Fatty (ZDF) rat (presented in Chapter 5) and the high fat fed, human islet 
amyloid polypeptide (hIAPP), transgenic mouse, presented in the current chapter.  The 
experimental approach for the animal studies is designed to reproduce the effects of Pb 
exposure in the human population, where obesity and diabetes risk factors are 
common.   
 
6.1 – human Islet Amyloid Polypeptide (hIAPP) Mouse Model 
In contrast to the ZDF rat, which possesses a genetic predisposition to obesity 
and diabetes due to hyperphagia, the hIAPP mouse is a high fat diet-induced transgenic 
rodent model that expresses the human islet amyloid polypeptide gene.  The hIAPP 
transgenic mouse was created to mimic a common pathophysiology of human Type 2 
diabetes, pancreatic amyloidosis [207, 208].  Amyloid deposits accumulate in pancreatic 
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islets in the vast majority of people with type 2 diabetes.  Amyloid is produced by β-cells 
of the islets and is co-secreted with insulin in response to changes in blood glucose 
[209-211].  And accumulation of amyloid plaques in pancreatic islets is associated with 
the progression of diabetes, including characteristic loss of beta-cell mass and function 
[207, 208].  The amyloid deposits that form in the pancreas are generated specifically 
from a pancreatic-specific amyloid called islet amyloid polypeptide (IAPP).  The 
amyloidogenic potential of IAPP is dependent on the sequence of the peptide, and the 
sequence of the protein produced in humans, non-human primates and cats is of the 
amyloidogenic form. The sequence of the gene in most rodents, including mice, is 
different and produces an islet amyloid protein that does not form plaques [212, 213].  
Because rodent IAPP is non-amyloidogenic, they do not experience the same amyloid-
dependent pancreatic dysfunction observed in humans, even in the face of similar 
metabolic stresses (i.e. peripheral insulin resistance).  Creation of hIAPP transgenic 
rodents allowed for expression of the human IAPP gene and amyloid aggregation & 
deposition in the pancreas under certain dietary conditions [169, 214].   
The hIAPP transgenic mouse strain is maintained in a C57Bl6 background [215-
217].  This mouse expresses the transgene specifically in beta cells (under the control 
of the rat INS2 promoter) but apparently does not develop diabetes, hyperglycemia or a 
pancreatic insufficiency [214].  However, when the hIAPP transgene is expressed in 
C57Bl6/DBA-2 F1 mice, pancreatic amyloid deposition and an elevated susceptibility to 
Type 2 diabetes occurs.  Previous studies observed a negative influence of estrogen on 
expression of the hIAPP transgene [169, 170], so only male C57Bl6/DBA-2 F1 hIAPP-
heterozygous transgenic mice were used in our study.  
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Because previously published data demonstrated that hIAPP transgenic mice 
required a minimum of 12 months on a high fat diet to develop pancreatic amyloid 
plaques, the experimental time frame for the hIAPP transgenic mice was lengthened 
from that of the ZDF rats (See Figure 6.1) [215].  This also allowed an extended period 
to observe what may be subtle effects of Pb exposure on the rate of diabetes 
progression. 
 
6.2 – hIAPP Experimental Setup 
Four groups of male hIAPP mice were established (the characteristics of which 
were described in the previous paragraphs).  Amounts of PbAc utilized in the hIAPP 
transgenic mouse study were based on previously published data [154], and the blood 
lead levels generated in my own ZDF rat experiment described above.  Two groups 
Fig. 6.1 – Experimental time line for hIAPP Mice.  
At 10 weeks of age, mice were placed on the high fat diet and treatment with Pb was initiated.  Bi-
weekly fasting blood glucose draws and bi-annual OGTTs were performed as shown above. Both high 
dose groups (n=16), both low dose groups (n=12). 
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(n=16) were treated with 0.02% w/v PbAc (“high treated”) or equimolar NaAc (“high 
control”) in the drinking water.  The other two groups (n=12) were treated with 0.005% 
w/v PbAc (“low treated”) or equimolar NaAc (“low control”) in the drinking water.  Male 
heterozygous hIAPP transgenic mice were started on the feeding/exposure protocol at 
10 weeks of age.  All animals were fed a standard chow diet (Purina 5009) until 
weaned, then placed on a high fat chow diet (Autoclavable Mouse Breeder Diet 5021, 
Purina) containing 9% fat w/w, (45% calories from fat) through termination (week 45 of 
the study, 55 weeks of age).  Food and water were offered ad lib.   
Body weights and food consumption were measured weekly; blood was drawn 
bi-weekly from fasted animals for blood glucose level determination.  Oral glucose 
tolerance tests (OGTTs) were performed before the initiation of treatment to establish 
baseline, and then repeated at 26 weeks and 40 weeks of treatment to look for changes 
in glucose tolerance.  After 45 weeks of exposure, animals were sacrificed following an 
8 hour fast by CO2 asphyxiation followed by cervical dislocation and exsanguination by 
cardiac puncture.  Relevant tissues were removed and portions placed in 4% buffered 
formalin at 4°C, freeze-clamped in liquid nitrogen or frozen in OTC for histological and 
molecular analyses.  Additional endpoint measures included plasma insulin and liver 
triglycerides. 
 
6.3 – Basic Parameters of the hIAPP Transgenic Model 
Pb exposure did not affect body weight (Figures 6.2 and 6.3) or food intake 
(Figures 6.4 and 6.5).  Blood lead levels were assessed by ICP-MS at Wayne State 
University School of Medicine’s Biochemistry Department (See Chapter 3 for protocol).  
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The average blood lead levels for the high treated animals, exposed to 0.02% w/v 
PbAc, was 41.5 μg/dL at termination (Figure 6.6).  The average blood lead levels for the 
low treated animals, exposed to 0.005% w/v PbAc, was 21.5 μg/dL at termination 
(Figure 6.7).  The lack of significant differences in body weight or food intake suggests 
that there were no major effects of Pb on appetite or activity with these levels of 
exposure. 
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Figure 6.2 – Body weight measures for hIAPP high dose (0.02% w/v) group.   
Data are means +/- SEM. High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40 
n=13, weeks 41-43 n=12, weeks 44-45 n=11. High treated: Weeks 0-20 n=16, weeks 21-28 
n=15, weeks 29-44 n=14, weeks 44-45 n=13. 
 
Figure 6.3 – Body weight measures for hIAPP low dose (0.005% w/v) group.   
Data are means +/- SEM. Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29 
n=10, weeks 30-35 n=9, weeks 36-40 n=8, weeks 41-45 n=7.  Low treated: Weeks 0-16 
n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8. 
 
75 
 
 
 
 
 
 
 
Fig. 6.4 – Food consumption measures for hIAPP high dose (0.02% w/v) group.   
High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40 n=13, weeks 41-43 n=12, 
weeks 44-45 n=11. High treated: Weeks 0-20 n=16, weeks 21-28 n=15, weeks 29-44 n=14, 
weeks 44-45 n=13. Data are means +/- SEM. 
 
Fig. 6.5 – Food consumption measures for hIAPP low dose (0.005% w/v) group.   
Data are means +/- SEM. Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29 
n=10, weeks 30-35 n=9, weeks 36-40 n=8, weeks 41-45 n=7.  Low treated: Weeks 0-16 
n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8. 
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Fig. 6.6 – Blood Pb levels at termination of hIAPP high dose (0.02% 
w/v) group.  Analysis completed by students T test.  Data are means 
with SEM, high control n=11, high treated n =13. *** p < 0.0002. 
Fig. 6.7 – Blood Pb levels at termination of hIAPP low dose (0.005% 
w/v) group.  Analysis completed by students T test.  Data are means 
with SEM, low control n=7, low treated n =8. **** p < 0.0001 
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6.4 – Pb Effects on Metabolic Parameters in hIAPP Transgenic Mice 
 An elevation in fasting blood glucose is a characteristic of Type 2 diabetes.  
Because the hIAPP transgenic mice were bred on to a DBA/2 background, they had a 
predisposition to develop insulin resistance, but are able to retain relatively normal 
blood glucose levels due to insulin hypersecretion in response to elevated blood 
glucose levels [218].  As shown in Figures 6.8 and 6.9, Pb exposure induced a 
persistent fasting hyperglycemia from 8 weeks of treatment, in both the high and low 
exposure groups as compared to the near-normal fasting blood glucose levels 
throughout the study of both control groups.   
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Fig. 6.8 – Fasting blood glucose measures for hIAPP high dose (0.02% w/v) group.   
Both groups began with normal fasting blood glucose levels (due to chance), but from week 8, 
the Pb-treated (high treated) group rose above the high control group.  Analyses by students 
T test, data are means +/- SEM. *p<0.05, **p<0.005, ****p<0.0001. 
High control: Weeks 0-16 n=11, weeks 17-34 n=15, weeks 35-40 n=13, weeks 41-43 n=12, 
weeks 44-45 n=11. 
High treated: Weeks 0-20 n=16, weeks 21-28 n=15, weeks 29-44 n=14, weeks 44-45 n=13. 
 
Fig. 6.9 – Fasting blood glucose measures for hIAPP low dose (0.005% w/v) group.   
Both groups began with normal fasting blood glucose levels (due to chance), but from week 4, 
the Pb-treated (low treated) group rose above the low control group.  Analyses by students T 
test, data are means +/- SEM. * p<0.05, ** p<0.005, *** p<0.0005 
Low control: Weeks 0-21 n=12, weeks 22-23 n=11, weeks 24-29 n=10, weeks 30-35 n=9, 
weeks 36-40 n=8, weeks 41-45 n=7. 
Low treated: Weeks 0-16 n=12, weeks 17-42 n=11, weeks 43-44 n=10, weeks 44-45 n=8. 
 
79 
 
 
 
Glucose intolerance, the inability to clear postprandial glucose from the 
circulation, is another characteristic of diabetes.  Complete OGTTs were performed 
after an 8 hour fast to establish a baseline (Time 0) and repeated at 26 weeks of 
treatment to observe changes in glucose tolerance.  Glucose tolerance was similar in all 
groups before the initiation of Pb exposure, but after 26 weeks of Pb exposure, the high 
dose group was more glucose intolerant compared to the controls, (Figure 6.10).  The 
low dose group behaved similarly; after 26 weeks of exposure, the Pb-treated group 
was glucose intolerant compared to the low control group although this difference did 
not achieve statistical significance (Figure 6.11).   
The increased glucose intolerance in the low dose animals is more clearly 
visualized when the data are rearranged to directly compare, the effect of time on 
glucose tolerance within a single treatment group.  OGTT data of the low control at 0 
and 26 weeks were plotted on one graph, while the same was done for the low treated 
(Figure 6.12).  When viewed in this manner it is clear that 6 months of Pb exposure 
induced glucose intolerance. The fasting hyperglycemia and glucose intolerance 
observed in both the high and low Pb-treated mice resembles that seen in the ZDF rats 
and further supports the idea that Pb exposure has a profound negative effect on 
glucose homeostasis in metabolically stressed rodents.  As stated previously, there are 
multiple mechanistic possibilities for how Pb might alter glucose metabolism, including 
reduced peripheral insulin sensitivity, defective glucose-mediated insulin secretion by 
the pancreas, and/or elevated hepatic glucose production. 
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Fig. 6.10 – Pb exposure causes glucose intolerance in 
high dose group.  
Oral glucose tolerance tests in hIAPP high treated (0.02% w/v) 
or high control after exposure to Pb for 0 or 26 weeks. The 
OGTT curves from the baseline measure are not different, 
while at 26 weeks, the high Pb-treated group is glucose 
intolerant compared to the high control group.  Time and 
treatment had an effect on glucose tolerance at 26 weeks as 
determined by ANOVA, *p<0.01. Data are means +/- SEM.  
Baseline: n=16 both groups.  26 weeks: n=15 both groups.  
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Fig. 6.11 – Pb exposure causes glucose intolerance in low 
dose group. 
Oral glucose tolerance tests in hIAPP low treated (0.02% w/v) 
or low control after exposure to Pb for 0 or 26 weeks.  The 
OGTT curves from the baseline differ only at 30 minutes 
(*p<0.01), while at 26 weeks, the low Pb-treated group is 
glucose intolerant compared to the low control group.  Data are 
means +/- SEM. Baseline: n=12 both groups.  26 Weeks: low 
control n=10, low treated n=11.  
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Fig. 6.12 – Data rearranged for direct comparison of effect of time on 
glucose tolerance. 
Oral glucose tolerance tests in hIAPP low treated (0.02% w/v) or low 
control after exposure to Pb for 0 or 26 weeks. Time of treatment had an 
effect on glucose tolerance at 26 weeks in the Pb treated group (*p<0.01) 
as demonstrated by ANOVA.  Data are means +/- SEM. Baseline: n=12 
both groups.  26 Weeks: low control n=10, low treated n=11. 
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To examine the possibility that Pb directly affects regulation of glucose 
production in the liver, changes in hepatic gluconeogenic gene expression in hIAPP 
transgenic mice were examined. Upon termination, mRNA was isolated from a small 
sample of flash-frozen liver tissue. Changes in gluconeogenic gene expression were 
quantified by two-step qRT-PCR with sequence-specific primers for PEPCK, G6Pase, 
PGC1-α and PPIA. These data showed that there was no significant difference in 
expression of any genes between Pb-exposed or control animals in either the high or 
low dose groups (Figures 6.13).  The gene expression results from the hIAPP mice 
differ from those observed in the ZDF rats. However, this is consistent with previously 
published data demonstrating that DBA/2 mice respond to elevated glucose by 
compensatory hypersecretion of insulin, and have been shown to have higher than 
normal plasma insulin levels during a fast, which could reduce hepatic gene expression 
levels [218].  A significant difference between the ZDF rat experiment and the mouse 
experiment, in this regard, was that the rats were sacrificed at termination after a fasting 
re-feeding protocol (described in methods), while the hIAPP mice were sacrificed after 
an 8 hour fasting-only protocol.   
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Fig. 6.13 – Pb exposure does not affect gluconeogenic gene expression in hIAPP mice. 
No changes in gluconeogenic gene (mRNA) expression were observed in either the high or low 
dose groups. Gene expression for PEPCK, G6Pase, PGC1α and PPIA was quantified by qRT-
PCR. Data are means with SEM relative to PPIA.  High control n=11, high treated n=13, low 
control n=7, low treated n=8. 
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To examine the effects of Pb exposure on pancreatic insulin production, insulin 
levels were determined in plasma samples from multiple time points throughout the 
study.  There was also an assessment of insulin levels during the 9 month OGTT at 
both the 0 and 60 minute time points.  Insulin ELISA results from the hIAPP mice did not 
show differences between Pb and control groups.  All groups displayed increasing 
insulin levels until week 40, when insulin levels decreased (Figure 6.14).  The insulin 
ELISA results from the 40 week OGTT 0 and 60 minute samples showed that the high 
treated animals not only appear to hypersecrete insulin when faced with a glucose 
challenge, but that they appear to have higher basal levels of insulin as well (Figure 
6.15).  The low dose mice did not show the expected increase in insulin levels after a 
glucose challenge.  Although the reason for this is not clear, it is clear that like the ZDF 
rats, Pb exposure did not cause a significant reduction in the capacity of the pancreas to 
produce insulin.  Although not directly measured, these results are consistent with the 
possibility that Pb induces deficiency in peripheral insulin sensitivity.   
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Fig. 6.14 – Pb exposure does not affect insulin production in hIAPP mice. 
Plasma insulin measured by ELISA showed increasing levels in all groups until week 40. After week 
40, both the low and high treated groups’ insulin levels decreased. Data showed no statistical 
significance by ANOVA and are means +/- SEM. Week 0 and 14: High control and treated n=16, 
Low control and treated n=12. Week 26: High control and treated n=15, Low control n=10 low 
treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated n=10. 
Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8. 
 
Fig. 6.15 – Pb exposure does not affect insulin production after glucose challenge. 
Plasma insulin measured at 40 weeks, before (0 Min) and after (60 Min) glucose bolus showed that 
high treated mice began with higher basal levels of insulin than control mice. While both groups’ 
insulin levels increase proportionally, the high Pb-treated mice appear to hypersecrete insulin.  The 
low dose mice show no significant difference at 0 and 60 minutes. Data showed no statistical 
significance by students T test. Data are means +/- SEM. 40 Weeks: High control n=13 high treated 
n=14, low control n=8, low treated n=10. 
 
87 
 
 
 
A small sample of flash-frozen liver tissue was analyzed for triglyceride content.  
These findings revealed that in the high treated animals, Pb exposure induced an 
accumulation of triglycerides in the liver (Figure 6.16).  Similar findings were observed in 
the low dose animals, although the differences were not statistically significant in this 
group.  Overall however, these data are strongly consistent with the findings from the 
ZDF rats; clearly demonstrating that Pb exposure induces hepatic steatosis in rodents.   
 
 
 
 
 
Fig. 6.16 – Pb exposure causes increased triglyceride accumulation in hIAPP mice. 
Liver triglycerides measures showed both high and low dose treated mice had greater accumulations 
of triglycerides within the liver tissue. Data analyzed by students T test. Data are means +/- SEM 
*p<0.05, **p<0.005.  High control n=11, high treated n=13, low control n=7, low treated n=8. 
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6.5 – Pb Exposure Effects on Histological Parameters 
To determine if Pb exposure affected liver morphology, a portion of the liver from 
each animal was subjected to standard histological analyses.  Hematoxylin and eosin 
(H & E) staining demonstrated that Pb exposure induced the accumulation of lipid 
droplets in liver.  This occurred at both doses and is consistent with the triglyceride 
assay presented above.  However, other than the lipid droplets, all of the mice had 
normal hepatic lobule structure (Figures 6.17, 6.18, 6.19 and 6.20), showing that Pb 
does not have a significant effect on gross liver morphology.   
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Fig. 6.18 – High treated liver H & E.   
Lipid droplets are visible within the hepatic tissue of high treated mice. 
Magnification 10x, bar = 200µm. 
Fig. 6.17 – High control liver H & E. 
Normal hepatic lobular structure is intact. Magnification 10x, bar = 200µm. 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 6.20 – Low treated liver H & E.   
Lipid droplets are visible within the hepatic tissue of low treated mice. 
Magnification 10x, bar = 200µm. 
Fig. 6.19 – Low control liver H & E. 
Normal hepatic lobular structure is intact. Magnification 10x, bar = 200µm. 
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Periodic Acid-Schiff (PAS) stain was used to determine if Pb had any effect on 
hepatic glycogen content or distribution.  A specimen that is PAS-positive will show 
glycogen (carbohydrates) as pink/magenta to purple-violet/red staining.  PAS staining 
revealed that liver from Pb-exposed animals contained less glycogen than control 
animals, as evidenced by the decreased level of PAS-positive staining in both the high 
and low Pb-treated mouse liver slides (Figures 6.21, 6.22, 6.23 and 6.24).  Glycogen 
depletion was further confirmed in the low dose animals by diastase digestion followed 
by PAS staining (Figures 6.23 and 6.24).  Diastase digestion is often used to confirm 
the presence of glycogen in tissue samples, as diastase digestion removes 
carbohydrates from tissues, thereby resulting in negative PAS staining in tissues that 
had previously been PAS-positive.  
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Fig. 6.22 – High treated liver PAS. Glycogen depletion after Pb exposure as 
evidenced by decreased PAS-positive staining (purple-violet coloration) in the 
Pb-treated liver.  Magnification 20x, bar = 100µm. 
 
Fig. 6.21 – High control liver PAS.  
Numerous PAS-positive glycogen deposits (purple-violet staining) are present 
in the control mouse liver.   Magnification 20x, bar = 100µm. 
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Fig. 6.23 – Low control liver PAS. Numerous PAS-positive glycogen deposits (purple-violet 
staining) are present in the undigested sample (left). But when digested (right), there is a 
dramatic loss of PAS-positive staining.   Magnification 5x, bar = 1mm. 
 
Fig. 6.24 – Low treated liver PAS. Glycogen depletion after Pb exposure as evidenced by 
decreased PAS-positive staining (purple-violet coloration) in the undigested (left) sample. 
Digestion (right) does not result in the same dramatic changes as seen in the control mouse 
above.   Magnification 5x, bar = 1mm. 
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 To determine if Pb exposure affected pancreatic morphology, a portion of the 
pancreas from each animal was subjected to standard histological analyses.  H & E 
staining demonstrated that Pb exposure does have an effect on islet morphology.  Both 
high and low control mouse islets appear normal, with a round shape and a well-defined 
border (Figures 6.25 and 6.27).  However, both high and low Pb-treated mouse islets 
are much larger in size than in control animals (Figures 6.26 and 6.28).   
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Fig. 6.25 – High control pancreas H & E.  
Islets are lighter stained, round areas.  Control mice appear to have normal islet 
physiology.  Magnification 10x, bar = 200µm. 
Fig. 6.26 – High treated pancreas H & E.  
Islets are lighter stained areas. Pb-treated mice appear to have hypertrophied 
islets. Magnification 10x, bar = 200µm. 
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Fig. 6.27 – Low control pancreas H & E. 
Islets are lighter stained, round areas.  Control mice appear to have normal islet 
physiology. Magnification 5x, bar = 1mm. 
Fig. 6.28 – Low treated pancreas H & E.  
Islets are lighter stained areas. Pb-treated mice appear to have hypertrophied 
islets. Magnification 5x, bar = 1mm. 
. 
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 Differences in islet sizes were quantified by measuring islet diameter and dividing 
them into 3 categories: small (<400µm), medium (>400µm - < 800µm) and large 
(>800µm).  Figures 6.29 and 6.30 illustrate the distribution of islet sizes in control and 
treated groups.  While the control groups show a higher proportion of islets in the 
smaller size categories, the Pb-treated groups show distributions strongly skewed to the 
larger size categories.  These findings clearly demonstrate that Pb exposure induces 
islet hypertrophy.  In addition, the subjective appearance of the islets from the Pb 
exposed mice indicates a general degradation of islet architecture, which is consistent 
with the possibility that these islets have at least some degree of compromised 
endocrinological function.  
 
 
Fig. 6.29 – Pb exposure affects islet size 
distribution in high dose group. Islets were 
counted and divided based on size. High Pb-treated 
mice had many larger islets, while the high control 
mice had many smaller size islets. Total number of 
islets assayed: 254-high treated and 264-high 
control. 
 
Fig. 6.30 – Pb exposure affects islet size 
distribution in low dose group.  Islets were 
counted and divided based on size. Low Pb-
treated mice had many larger islets, while the 
low control mice had many smaller size islets. 
Total number of islets assayed: 261-low 
treated and 265-low control. 
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Noting the Pb-mediated alterations in islet morphology, I wanted to determine if 
Pb exposure affected the prevalence of β-cells in pancreatic islets.  Aldehyde Fuchsin is 
commonly used to detect islets and β-cells in pancreatic tissue samples as blue to violet 
or purple punctate in color.  Although not easily quantified, the density of dark blue 
punctate staining appeared to be increased in the Pb exposed animals.  However, 
because the Pb-treated islets are much larger, both groups appear to have the same 
proportion of β-cells (Figures 6.31, 6.32, 6.33 and 6.34).  These findings, while not 
striking, suggest that the increased islet size in Pb-treated mice is related to Pb-
dependent processes occurring within the islets of these mice. 
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Fig. 6.31 – High control pancreas Aldehyde Fuchsin.  
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells. 
Magnification 20x, bar = 100µm. 
Fig. 6.32 – High treated pancreas Aldehyde Fuchsin.  
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells. 
Magnification 20x, bar = 100µm. 
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Fig. 6.33 – Low control pancreas Aldehyde Fuchsin.  
Arrows indicate location of islets, and Aldehyde Fuchsin-positive β-cells. 
Magnification 20x, bar = 100µm. 
 
Fig. 6.34 – Low treated pancreas Aldehyde Fuchsin.   
Arrows denote the edge of the islet (which is too large for the field of view) and 
Aldehyde Fuchsin-positive β-cells. Magnification 20x, bar = 100µm. 
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6.6 – Pb Exposure Causes Increased Amyloid Plaque Formation 
 The transgenic mouse model utilized in this study was specifically created to 
more closely mimic the human form of diabetes, including amyloid plaque formation.  To 
determine the extent of amyloidosis within the pancreatic islets of the hIAPP transgenic 
mice, a specialized stain for amyloid was utilized.  Congo Red is commonly used to 
detect amyloid in pancreatic tissue samples, it appears as a bright pink/red stain in a 
bright field microscope; while polarized light shows it as an apple-green birefringence.  
As is evident from the photos below, both the high and low treated mice had 
significantly greater amyloid accumulation within the pancreatic islets (Figures 6.35, 
6.36, 6.37 and 6.38).   
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Fig. 6.35 – High control pancreas Congo Red, bright field.  
Lighter stained areas are islets, pink inside islets is amyloid. Control mice had 
very little amyloid. Magnification 5x, bar = 1mm. 
 
Fig. 6.36 – High treated pancreas Congo Red, bright field.  
Bright pink and red areas are amyloid positive inside of islets. Treated mice had 
significantly more amyloid depositions. Magnification 5x, bar = 1mm. 
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Fig. 6.37 – Low control pancreas Congo Red, bright field (left) and polarized (right).  
Lighter stained areas are islets; pink inside islets is amyloid (left). Apple-green bi-refringence inside 
islets is amyloid deposits. Control mice had very little amyloid. Magnification 5x, bar = 1mm (left), 
magnification 10x (right). 
 
Fig. 6.38 – Low treated pancreas Congo Red, bright field (left) and polarized (right).  
Lighter stained areas are islets; bright pink-red inside islets is amyloid (left). Apple-green bi-
refringence inside islets is amyloid deposits. Treated mice had significantly more intra-islet amyloid. 
Magnification 5x, bar = 1mm (left), magnification 10x (right). 
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Quantification of the portion of the islet covered with amyloid was carried out by 
dividing islets into 4 categories: no amyloid, low = <1/3 amyloid coverage, medium = 
>1/3-<2/3 amyloid coverage and high = >2/3 amyloid coverage (Figures 6.39 and 6.40).  
These findings are striking and clearly demonstrate that Pb-exposure exacerbates 
amyloid plaque formation in pancreatic islets.  
 
 
 
 
 
 
Fig. 6.40 – Pb exposure increases amyloid 
plaque formation in low dose group. Islets 
were assessed based on surface area filled with 
amyloid. Low Pb-treated mice had significantly 
fewer islets with no amyloid than the low control 
mice. Total number of islets assayed: 261-low 
treated and 265-low control. 
 
Fig. 6.39 – Pb exposure increases amyloid 
plaque formation in high dose group. Islets were 
assessed based on surface area filled with amyloid. 
High Pb-treated mice had significantly fewer islets 
with no amyloid than the high control mice. Total 
number of islets assayed: 254-high treated and 
264-high control. 
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6.7 – Pb Exposure Affects Liver: Body Weight Ratios 
Upon termination and dissection of organs, I noted that livers from control 
animals appeared larger than livers from Pb-exposed animals. This observation was 
confirmed when the whole excised livers were weighed and liver weights graphed as 
percent of body weight (Figure 6.41).  Both the high and low Pb-treated mice had 
significantly lower liver-to-body weight ratios than the control mice from both groups.  
This was an unexpected finding, especially considering the observed Pb-induced 
hepatic steatosis (Figure 6.16), which is usually associated with increased liver weight. 
 It is well-known that there is a negative correlation between liver size and age 
[219-221] and it is possible that Pb exposure accelerated this age-related effect on liver 
size, although the mechanism by which this might occur remains obscure. 
 
Fig. 6.41 – Pb exposure affects liver: body weight ratios in hIAPP mice. 
Whole liver weights obtained at sacrifice showed that both the high and low Pb-treated 
mice had significantly lower liver-to-body weight ratios compared to controls. Data 
analyzed by students T test. Data are means +/- SEM *p<0.05, **p<0.005.  High control 
n=11, high treated n=13, low control n=7, low treated n=8. 
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6.8 – Pb Exposure, Whole-Body Insulin Resistance and β-Cell Function  
Our lab is not equipped to assess insulin sensitivity by direct measure, so I 
utilized an assessment tool that has been widely used in human epidemiological 
studies, but is given mixed acceptance when applied to animal studies.  The 
homeostatic model assessment (HOMA) is a technique utilized to estimate insulin 
resistance and beta-cell function from insulin and fasting blood glucose samples 
obtained at the same time.  The original HOMA-IR technique, developed in 1985, was 
utilized extensively, particularly in clinical and epidemiological studies  [222].  However, 
the 1985 model did not consider differences in peripheral and hepatic insulin sensitivity, 
alterations in insulin secretion or hepatic glucose output when fasting blood glucose 
measured above 180 mg/dL, or the presence of circulating pro-insulin.  To take into 
consideration all of these differences, a modified version of the analysis, termed 
HOMA2-IR, was created [223].  The HOMA2-IR model utilizes a computer modeling 
program that calculates a corrected nonlinear estimation of insulin resistance (IR) and 
percent beta-cell function (% β-cell function).  A number of empirical equations 
(nonlinear) are utilized by the HOMA2-IR computer program to predict numerical values 
from paired fasting blood glucose and insulin samples.  I downloaded the HOMA2-IR 
calculator and utilized the fasting blood glucose and insulin measures from weeks 0, 14, 
26, 40 and 45 of treatment to view estimated numerical values for the calculations of IR 
and % β-cell function between treated and control groups [224]. 
As demonstrated in Figures 6.42 and 6.43, all groups experienced progressively 
increasing insulin resistant and beta-cell function.  However, there appears to be a trend 
toward greater peripheral insulin resistance in the high treated group.  This is not, 
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however a confirmation of insulin resistance and it did not reach statistical significance.  
The β-cell graph is consistent with not seeing differences in insulin levels and changes 
in β-cell function are directly associated with insulin sensitivity.  Increased beta-cell 
function is indicative of decreased peripheral insulin sensitivity and may correlate with β-
cell hyperplasia. 
 
 
 
 
Fig. 6.42 – Pb exposure affects whole-body insulin resistance in hIAPP mice. 
Whole-body insulin resistance as calculated by HOMA2-IR (units are arbitrary) demonstrated that 
all groups experienced progressively increasing insulin resistance (IR≤1.0 = non-insulin resistant, 
IR>2.7 = insulin resistant). Data are means +/- SEM. Weeks 0 and 14: High control and treated 
n=16, Low control and treated n=12. Week 26: High control and treated n=15, Low control n=10 low 
treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated n=10. 
Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8. 
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6.9 – Additional Histological Observations 
Liver tissue was examined for fibrosis with Masson’s Trichrome stain, but there 
was no discernible difference between the control and Pb-treated in either the high or 
low dose groups (data not shown).  Pancreatic tissue was also examined for fibrosis 
with Masson’s Trichrome Stain, and while there was some fibrosis present, there was 
no discernible difference in the degree of fibrosis between the control and Pb-treated in 
either the high or low dose groups (data not shown).   
 
6.10 – Discussion of hIAPP Study 
The experiments conducted in the hIAPP transgenic mouse model were 
designed to determine if Pb-exposure was pro-diabetic in animals with high fat diet-
induced obesity, and to specifically determine if Pb-exposure exacerbated the islet 
amyloid deposition characteristic of advanced Type 2 diabetes in humans.   
Fig. 6.43 – Pb exposure affects Beta-cell function in hIAPP mice. 
Percent beta-cell function, as calculated by HOMA2-IR (%B=100 = normal beta-cell function, 
%B>100 = increased beta-cell function). Data are means +/- SEM. Weeks 0 and 14: High control and 
treated n=16, Low control and treated n=12. Week 26: High control and treated n=15, Low control 
n=10 low treated n=11. Week 40: High control n=13, high treated n=14, low control n=8, low treated 
n=10. Week 45: High control n=11, high treated n=13, low control n=7, low treated n=8. 
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It is clear from the data presented here, that Pb exposure, even at 0.005% w/v, in 
combination with the high fat diet, promotes the development of diabetes in hIAPP 
transgenic mice, specifically causing the development of fasting hyperglycemia and 
glucose intolerance over time.   
Even though the hIAPP mice did not experience the same Pb-mediated 
elevations in gluconeogenic gene expression as the ZDF rats, this may be accounted 
for by differences in termination procedures as well as differences in the physiology of 
the two rodents.  The ZDF rats were sacrificed under a fasting/re-feeding protocol that 
would reveal defects in insulin-mediated suppression of hepatic gluconeogenesis.  The 
hIAPP mice, on the other hand, were sacrificed after a simple overnight fast (no re-
feeding period), and liver gene expression levels would be more indicative of the inter-
meal state, rather than the post-prandial state.  In addition, I observed that basal insulin 
levels were higher in hIAPP mice (Figures 6.14 and 6.15) than in ZDF rats (Figure 5.9) 
which could potentially cause a background suppression of hepatic gene expression 
that overpowered any effects of Pb-exposure.   While the dysregulation of the insulin-
mediated suppression of hepatic gluconeogenic gene expression observed in ZDF rats 
was not seen in the hIAPP mice; the combination of elevated insulin and blood glucose 
levels in the hIAPP mice is suggestive of hepatic insulin resistance.  
Consistent with this possibility is the observation of hepatic steatosis in the Pb-
treated animals.  Fatty liver is frequently observed in insulin resistant humans and 
animal models and is associated specifically with hepatic insulin resistance [201-203].  
The hepatic lipid accumulation in both models may be secondary to the hyperglycemia 
we observed, which has been shown to be a “trigger” that stimulates de novo synthesis 
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of hepatic lipids [204, 205].  Also consistent with Pb-induced metabolic dysfunction 
centered on the liver, is the observation that livers from Pb exposed rats were glycogen 
depleted (Figures 6.21, 6.22, 6.23 and 6.24).  Glycogen depletion has been associated 
with elevated fasting blood glucose [200, 206], and may also be consistent with hepatic 
insulin resistance.  Although not necessarily indicative of hepatic insulin resistance, the 
HOMA2-IR assessment (Figures 6.42 and 6.43) demonstrated progressive overall 
insulin resistance and increased beta-cell function in the hIAPP mice. 
And, while it may seem contradictory, the significant differences in liver-to-body 
weight ratios actually accentuate the data showing that Pb exposure affects normal 
hepatic function.  It is well-known that there is a negative correlation between liver size 
and age [219-221].  Decreases in hepatic blood flow are common with age and studies 
have shown that decreased ability to clear toxins has caused drug overdoses in the 
elderly [219, 220, 225].  It is possible that the age-related effect on hepatic blood flow 
decreased clearance of Pb from the liver and exacerbated its effects on hepatic 
physiology, including the age-related decrease in liver size. 
Examination of gross pancreatic morphology by use of H & E staining revealed 
Pb-induced islet hypertrophy in both high and low treatment groups.  This may be 
related in part to the strikingly higher level of amyloid deposition in exposed animals. 
The data also suggest an increase in beta-cell numbers in the Pb-treated groups, which 
may be indicative of classic islet compensation in response to mounting global insulin 
resistance, which clearly occurred in the exposed mice (Figures 6.42 and 6.43).  
Amyloid accumulations are suggestive of pancreatic dysfunction, which is somewhat 
contrary to the observation that insulin levels were not substantially different in Pb-
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exposed vs. control mice.  As with the ZDF rats, it appears that while there are striking 
Pb-induced islet abnormalities, these alterations are not enough to cause pancreatic 
failure, at least within the timeframe of these experiments.   
Our results do not rule out the possibility that Pb affects peripheral insulin 
resistance in these mice.  Unfortunately, a direct measurement of peripheral insulin 
sensitivity in intact animals is difficult and was beyond the technical scope of our lab and 
my thesis.  However, the calculations provided by HOMA2-IR for insulin resistance and 
beta-cell function demonstrated a trend in increasing whole-body insulin resistance that 
may be accompanied by peripheral insulin resistance. 
My findings demonstrate for the first time that Pb promotes the development of 
diabetes in a high fat fed transgenic mouse model.  I identified Pb-induced defects in 
both hepatic glucose output and in postprandial glucose clearance.  Both of these are 
insulin mediated processes and it seems likely that Pb is interfering with insulin 
signaling, at least in liver, and possibly also in muscle.  The data also identified key 
histological aspects of Pb-exposure, including islet abnormalities and increased β-cell 
compensation.  Additionally, the data showed striking Pb-induced exacerbations of 
amyloid plaque formations in pancreatic islets.  These findings demonstrate that, in 
metabolically stressed rodents, Pb exposure increases susceptibility to diabetes and 
promotes progressive development of metabolic abnormalities.   
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Chapter 7 – Exploring the Molecular Mechanism of Pb Action 
 
The in vivo data presented above demonstrate that Pb exposure causes fasting 
hyperglycemia, glucose intolerance and elevated hepatic gluconeogenic gene 
expression.  The dysregulation of the insulin-mediated suppression of hepatic 
gluconeogenic gene expression and hepatic insulin resistance could be major 
contributors to these in vivo observations.  To examine the effects of Pb on hepatic 
physiology I developed a set of hepatic cell culture systems that reflect the in vivo 
consequences of Pb exposure.  The overall goal of the in vitro studies using these 
systems was to characterize the molecular mechanisms by which Pb alters hepatic 
insulin sensitivity and gluconeogenesis.  The two aims for this portion of my thesis were 
to: 1) determine if Pb exposure alters gluconeogenic gene by interfering with insulin 
signaling and 2) determine if Pb exposure alters gluconeogenic gene expression by 
interfering with Rev-erb-α activity.  
 
7.1 – Development of the Model Cellular System 
The in vivo data described in chapters 5 and 6 suggest that one of the metabolic 
effects of Pb exposure in obese rats and mice is to suppress the ability of the liver to 
regulate glucose production.  Pb concentrations which correlate with blood Pb levels 
observed in Pb-exposed individuals were utilized in an effort to make this in vitro system 
more clinically relevant [226-229].  In order to decipher the molecular mechanism(s) 
responsible for the hepatic effects of Pb, and begin development of the in vitro model 
systems, the effect of Pb exposure on hepatic gluconeogenic genes in cultured primary 
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rat hepatocytes (PRH) and in two rat hepatoma cell lines were assessed.  Extensive 
optimization experiments in all three cell systems were carried out to determine 
hormonal conditions, treatments times and Pb exposure levels that generated effects on 
gluconeogenic gene expression that were most consistent with the in vivo findings (data 
not shown).   
As will be described in more detail below, the results from these experiments 
were consistent with the animal studies in that treatment of liver cells with Pb increased 
expression of the two key gluconeogenic genes (PEPCK and G6Pase), as well as the 
transcriptional co-activator PGC1-α, which is a strong transcriptional activator of 
gluconeogenic gene expression in liver. This effect was seen both on basal gene 
expression (Section 7.2) and in the context of insulin mediated suppression of gene 
expression (7.3).  
 
7.2 – Pb Stimulates Basal Expression of Key Gluconeogenic Genes 
The rat hepatoma cell line FAO was used to examine the effect of Pb on basal 
levels of gluconeogenic gene expression.  The cells were cultured in serum containing 
media in the presence of low levels of insulin.  After a 2 hour serum deprivation period 
(during which insulin levels were maintained at 1nM) cells were treated with 5µM PbAc 
or equimolar NaAc for 8 hours.  Cells were washed, lysed by direct application of Tri 
reagent and placed on ice.  After mRNA isolation, first-strand cDNA synthesis was 
conducted and changes in gluconeogenic gene expression were quantified by qRT-
PCR with primers for PEPCK, G6Pase, PGC1-α and the housekeeping gene, PPIA.  As 
shown in Figure 7.1, exposure to Pb induced the expression of genes encoding key 
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Fig. 7.1 – Pb stimulates the expression of key genes involved in hepatic glucose output in 
FAO cells.  
Cells were treated with 5µM PbAc or equimolar NaAc in the presence of 1nM insulin. Changes in 
expression of key genes (mRNA) were quantified by qRT-PCR with sequence-specific primers. 
Data are the mean +/- SEM of three independent experiments. Values are normalized to PPIA; 
p*<0.05, p***<0.001. 
 
rate-limiting enzymes involved in glucose biosynthesis (PEPCK and G6Pase) and of the 
PGC1-α gene that encodes a transcriptional co-activator that plays a key stimulatory 
role in PEPCK gene transcription.  
 
 
The data from the FAO cells was supported by collaborative profiling data 
generated by Dr. Raymond Novak and Dr. Lowell Overton, Wayne State University 
Institute of Environmental Health Sciences (Figure 7.2).  The profiling experiments were 
conducted in PRH cells treated for 24 hours with 1µM Pb (left panel) and 0.5µM or 
5.0µM Pb (right panel) in the presence of the indicated amount of insulin (0, 0.1nM, 
1nM, 10nM).  These data confirm that Pb exposure stimulates mRNA expression of a 
key gluconeogenic co-factor, PGC1-α, as seen in FAO cells.  It was noted that PGC1-α 
gene expression was stimulated in the presence of Pb, but only when insulin was 
present.   
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7.3 – Pb Blocks Insulin-Mediated Down-Regulation of PEPCK Gene Expression 
 Based on data from both FAO cells and preliminary profiling showing that PGC1-
α gene expression was stimulated by Pb, but only when insulin was present (Figures 
7.1 and 7.2), I proposed that the primary effect of Pb on liver glucose metabolism might 
be to oppose the well-known insulin-mediated down-regulation of gluconeogenic gene 
expression.  To examine this, two well-established in vitro cellular models for hepatic 
insulin signaling pathways related to glucose production were utilized, primary rat 
hepatocytes and H4IIe rat hepatoma cells (the parent cell line of the FAO cells used 
above).  The pharmacological reagent dexamethasone (Dex) is a glucocorticoid mimic 
that is utilized in vitro to stimulate PEPCK gene expression.  In this in vitro system, the 
effect of insulin on gluconeogenic gene expression is more readily observed in the 
presence of dexamethasone.  H4IIe cells were serum-starved for 12 hours then treated 
Fig. 7.2 – Pb stimulates the expression of PGC1-α in the presence of insulin.  
Primary rat hepatocytes were treated with 1µM (left panel) or with the indicated amount of Pb (right 
panel) for 24 hours in the presence of the indicated amount of insulin. In the left panel, note the 
suppressive effect of insulin on PGC1-α expression in the absence of Pb. The data in the right panel 
(from a separate RNA profiling experiment) are normalized to the vehicle (no Pb) control at each insulin 
concentration. Data for left panel are preliminary and were not repeated.  Data for right panel are 
means +/- SD for two experiments. Data courtesy of Dr. Raymond Novak and Dr. Lowell Overton; 
unpublished. 
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with 500nM dexamethasone (Sigma), 500nM dexamethasone + 10nM Insulin, 10nM 
Insulin alone, or vehicle for 4 hours, in the presence of either 50µM PbAc or equimolar 
NaAc.  Cells were washed with cold PBS after removal of media, lysed with direct 
application of Tri reagent and placed on ice.  After mRNA isolation, first-strand cDNA 
synthesis was conducted and utilized in semi-quantitative PCR with primers specific for 
rat PEPCK and housekeeping gene, PPIA.  Final PCR products were analyzed by 
agarose gel electrophoresis and quantitative image analysis using a ChemiDoc XRS 
imaging system.  Band densities were analyzed using the NIH Image J program 
(described in further detail Section 3.10.2).   
 Figure 7.3 shows the timeline of the experiment, the compiled quantitative data 
from three experiments (bar graph) and representative agarose gels of semi-
quantitative PCR runs.  Figure 7.4 is a subset of the same data from Figure 7.3 
assembled for illustrative purposes, to allow an easier comparison between Na-treated 
and Pb-treated groups.   
The data demonstrate that Pb exposure blocks the suppressive effects of insulin 
on PEPCK gene expression.  It is also important to note that the ability of Pb to block 
insulin’s suppressive effect occurs even in the absence of dexamethasone (last pair of 
bars in Fig. 7.4). 
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Fig. 7.3 – Pb blocks insulin-mediated down-regulation of PEPCK gene expression.  
H4IIe cells treated with 500nM Dex, 500nM Dex + 10nM Insulin, 10nM Insulin or Vehicle 
(DMSO, PBS & dH2O) for 4 hours plus either 50µM PbAc or 100µM NaAc.  Data are means 
+/- SEM of three independent experiments.  
 
 
 
PEPC
K 
PPIA 
Fig. 7.4 – Subset of data from Figure 7.3.  
Clearly demonstrates the ability of Pb to block insulin-mediated down-regulation of PEPCK 
gene expression. H4IIe cells treated with 10nM Insulin or Vehicle (DMSO, PBS & dH2O) for 4 
hours plus either 50µM PbAc or 100µM NaAc.  Data are means +/- SEM of three independent 
experiments. P values relative to PPIA control, ** p< 0.001 
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Similar experiments in primary hepatocytes showed analogous results.  PRH 
cells were plated on collagen-coated plates in insulin-containing media and allowed to 
recover overnight.  Cells were subjected to a 2 hour incubation in insulin-free media and 
then treated with 50μM PbAc or equimolar NaAc and either PBS (Veh) or 10nM insulin 
for 24 hr. Semi-quantitative PCR carried out as described above generated the results 
shown in Figure 7.5.  Pb blunted the insulin-mediated suppression of PEPCK gene 
transcription in PRH cells in a manner similar to that seen in H4IIe cells in Figure 7.3 
and in the right hand panel of Figure 7.5.       
These gene expression results are consistent with the observation made by our 
colleagues Ray Novak and Lowell Overton (WSU IEHS) who kindly provided data from 
an experiment in primary hepatocytes showing the insulin mediated Akt phosphorylation 
was suppressed by Pb (Figure 7.6).  As Akt mediates the insulin signal leading to 
suppression of FoxO1, which is required for PEPCK, G6Pase and PGC1-α expression 
Fig. 7.5 – Pb blunts the ability of insulin to suppress PEPCK gene expression.  
Primary rat hepatocytes (left) were treated with 50μM PbAc or equimolar NaAc and either PBS 
(Veh) or 10nM insulin for 24 hr.  PEPCK mRNA levels were measured by qRT-PCR with 
sequence-specific primers.  Data for PRH cells are preliminary and were not repeated.  The 
same experiment was conducted in H4IIe rat hepatoma cells (right) except that treatment time 
was for 4 hours. In both cell systems, Pb strongly blunted the suppressive effects of insulin. 
Data for H4IIe cells are the mean +/- SEM of three independent experiments.   
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(see Figure 2.1).  These findings suggest a possible mechanism by which Pb exposure 
alters insulin-mediated changes in gene expression.   
 
7.4 – Pb, Rev-erb-α and Effects on Basal PEPCK Gene Expression 
 To examine the effects of Pb exposure on basal PEPCK gene expression in 
relation to the orphan nuclear receptor Rev-erb-α, H4IIe rat hepatoma cells were 
utilized.  Emerging evidence indicates that components of the circadian clock machinery 
can regulate expression of metabolic genes, including PEPCK, G6Pase and PGC1-α 
[155].  This evidence was further supported by data gathered from mice with mutated 
Clock genes showing abnormal gluconeogenic gene expression [156-158].  However, 
the mechanism that links metabolic gene expression to circadian clock rhythms remains 
poorly understood.  
 Recently, studies have shown that heme functions as an endogenous ligand for 
the orphan nuclear receptor Rev-erb-α, a known component of the circadian clock 
Fig. 7.6 – Pb inhibits Akt phosphorylation in presence of insulin. 
Primary rat hepatocytes were treated with increasing concentrations of insulin for 24 hours, which 
resulted in a dose-responsive increase in Akt phosphorylation (left part of figure).  This   insulin-
mediated phosphorylation of Akt was strongly suppressed by the inclusion of 0.5µM Pb in the media 
and completely blocked by 5µM Pb. Data were preliminary, not repeated, and are courtesy of Dr. 
Raymond Novak and Dr. Lowell Overton; unpublished. 
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machinery [159].  Rev-erb-α is highly expressed in multiple tissues including liver, and 
functions as a transcriptional repressor [160, 163].  When heme is bound, it facilitates 
the interaction of Rev-erb-α with the nuclear receptor corepressor-histone deacetylase 3 
(NCoR-HDAC3) complex [160-162].  When heme binds to Rev-erb-α it initiates 
recruitment of the NCoR-HDAC3 complex and suppresses the transcription of Rev-erb-
α target genes including PEPCK, G6Pase and PGC1-α [161].  It is well established that 
Pb interferes with heme biosynthesis by direct inhibition of δ-aminolevulinic acid 
synthetase (δ-ALAS), δ-aminolevulinic acid dehydratase (δ-ALAD) and causing an 
accumulation of the known pro-oxidant, δ-ALA [164-167].  Taken together, these 
observations suggest the following model (Figure 7.7).  Pb exposure leads to 
suppression of heme biosynthesis and a reduction in intracellular heme levels.  The 
reduction in intracellular heme leads to reduced ability of Rev-erb-α to suppress gene 
transcription and thereby an increase in the expression of PEPCK, G6Pase and PGC1-
α.  The resulting increase in gluconeogenic gene expression will lead to elevated 
hepatic glucose production, contributing to the pathogenesis of diabetes.  
 The overall experimental strategy to test this model is divided into three stages.  
First, establish a system in hepatoma cell lines and primary hepatocytes in which we 
can confirm the previously reported effects of heme on PEPCK and G6Pase 
transcriptional activity.  Commercially available well-characterized reagents to artificially 
alter intracellular heme levels were used to establish the experimental parameters.  
Succinyl acetone (Sigma D1415) to suppress heme biosynthesis and hemin, (Sigma 
H9030) to increase intracellular heme levels were used as previously described [159, 
161].  Once this system was established it was to be used to examine the specific role 
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of Rev-erbα in regulation of PEPCK and G6Pase gene transcription.  This was to be 
accomplished using a combination of luciferase reporter constructs containing highly 
specific Rev-erb-α DNA binding sites (ROREs) upstream of a minimal promoter, as well 
as PEPCK and G6Pase promoter/reporter constructs that we already have available in 
the lab.  The ability of Pb to reduce the suppressive activity of Rev-erb-α on PEPCK and 
G6Pase gene transcription would constitute evidence in support of the model described 
above. 
Extensive optimization experiments in multiple cell lines (H4IIe hepatoma, CHO, 
NIH 3T3 and HepG2 cells) were conducted to elicit an effect of Pb on Rev-erb-α.  While 
I was able to observe an effect from exogenous heme on luciferase reporter gene 
activity, the results were inconsistent; and, to date, I have been unable to see a clear 
effect of Pb on Rev-erb-α activity (data not shown).  
 
 
 
 
 
 
 
Fig. 7.7 – Rev-erb-α model for how Pb stimulates PEPCK gene expression. 
 Based on recently published data demonstrating the link between Rev-erb-α and 
its ligand, heme; along with the ability of Pb to suppress heme biosynthesis.  
 
122 
 
 
 
7.5 – Discussion of In Vitro Studies 
PEPCK gene expression is controlled by multiple transcription factors and co-
factors.  Some of the transcription factors that play key roles in PEPCK gene expression 
are FoxO1, Rev-erb-α and the co-activator, PGC1-α [141, 230-233].  Hepatic insulin 
signals involving Akt-mediated phosphorylation and subsequent translocation of FoxO1 
outside of the nucleus plays a central role in regulation of PEPCK gene transcription 
[234-236].  The transcriptional rate of PEPCK gene plays a major role in regulating 
hepatic glucose production and output, and its suppression by insulin plays a key role in 
the maintenance of normal plasma glucose levels.  Therefore, in an effort to 
characterize the molecular mechanism of Pb in the liver, the in vitro system was 
optimized to observe maximal effects of Pb on PEPCK. 
Although I was able to show clearly that Pb exposure in vitro caused an elevation 
in PEPCK gene expression and a reduction in the ability of insulin to suppress PEPCK 
expression, I was not successful in identifying the exact molecular mechanism by which 
this occurred.  The two proposed mechanisms; blocking insulin signaling upstream of 
Akt, and reducing the suppressive effects of Rev-erb-α by blocking production of its 
ligand heme, are still both viable possibilities.  
The combination of data presented here related to alterations in gluconeogenic 
gene expression and insulin signaling in PRH and rat hepatoma cells after Pb exposure 
suggests that a major consequence of Pb in the liver is hepatic insulin resistance.  
Figure 7.8 is proposed as a model for the role of Pb involvement in insulin signaling. 
As described above, the results from these experiments are consistent with the 
animal studies; in vitro treatment of liver cells with Pb either induced the expression of 
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genes that are required for hepatic glucose production (PEPCK, G6Pase, and PGC1-α), 
or blocked the ability of insulin to down-regulate these genes.  The dysregulation of the 
insulin-mediated suppression of hepatic gluconeogenic gene expression could be a 
major contributor to the hyperglycemia observed in the animal studies and further 
supports the supposition that Pb exposure causes hepatic insulin resistance.  Together, 
these observations suggest that Pb exposure interferes with insulin signaling, inducing a 
hepatic insulin resistance that compromises the ability of the liver to control glucose 
production and promotes the development of hyperglycemia, consistent with in vivo 
observations.     
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Fig. 7.8 – Hypothetical model of how 
Pb may inhibit insulin signaling. 
This model is based on preliminary data 
of how Pb functions to alter insulin 
signaling and hepatic gluconeogenesis 
in the liver. 
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An important and unresolved question in the environmental health field is 
whether exposure to common environmental toxicants, such as dioxin and heavy metals 
like Pb, increase the risk of developing diabetes, especially in combination with other 
common metabolic stressors such as obesity.   
Previous studies suggested that dioxin exposure increased peripheral insulin 
resistance but did not appear to cause fasting hyperglycemia or elevated hepatic 
glucose output.  In concordance with those findings we observed that dioxin treatment 
caused a strong suppression of the expression of the key hepatic gluconeogenic genes 
PEPCK and G6Pase.  However, this suppression was not solely mediated by the dioxin 
(AhR) receptor as we observed that dioxin treatment stimulated the AMPK signaling 
pathway, which is known to have a suppressive effect on PEPCK gene expression. 
Although Pb exposure and blood Pb levels have declined over the past decade, 
the interaction between obesity and Pb exposure is a relevant issue in large sections of 
the US population where environmental and lifestyle factors co-exist with exposure to 
persistent environmental toxicants, such as Pb.  We characterized the effect of Pb 
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exposure on diabetes risk in metabolically stressed rodents and attempted to identify 
the in vitro mechanisms by which Pb affects metabolic balance.   
These findings demonstrate for the first time that, in metabolically stressed 
rodents, Pb exposure promotes the development of Type 2 diabetes.  In ZDF rats we 
identified Pb-induced defects in hepatic glucose output and postprandial glucose 
clearance as well as key histological aspects of Pb-exposure, including islet 
abnormalities and increased β-cell compensation.  And in hIAPP transgenic mice we 
demonstrated that Pb exposure, in combination with a high fat diet, caused the 
development of fasting hyperglycemia and glucose intolerance as well as Pb-induced 
islet hyperplasia and striking pancreatic amyloid plaque formation.  In vitro data from 
cultured hepatocytes clearly showed that Pb exposure either induced the expression of 
genes that are required for hepatic glucose production (PEPCK, G6Pase, and PGC1-α), 
or blocked the ability of insulin to down-regulate those genes,  which would contribute to 
the development of hyperglycemia in vivo.  Together, these observations suggest that 
Pb exposure interferes with insulin signaling, inducing a hepatic insulin resistance that 
compromises the ability of the liver to control glucose production.   
Understanding the cooperative interaction between toxicant exposure and 
additional physical and social stressors that may promote metabolic instability and 
disease will be of enormous significance in delineating disease/toxicant etiology as well 
as establishing earlier interventions for those populations most at risk.  
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